
<!DOCTYPE html>
<html lang="en">
    <head>
        <title>Case Study: MH_dev_57</title>
    </head>
<style type="text/css">
    /* gridtable */
    table.gridtable {
        font-family: verdana,arial,sans-serif;
        font-size:11px;
        color:#333333;
        border-width: 1px;
        border-color: #666666;
        border-collapse: collapse;
    }
    table.gridtable th {
        border-width: 1px;
        padding: 8px;
        border-style: solid;
        border-color: #666666;
        background-color: #dedede;
    }
    table.gridtable td {
        border-width: 1px;
        padding: 8px;
        border-style: solid;
        border-color: #666666;
        background-color: #ffffff;
    }
    /* /gridtable */
    
    </style>
    
    <body style="font-size: 16px; font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol'; padding: 4rem 2rem; direction: ltr">
<figure style="margin-bottom: 6rem">
    <h1>MH_dev_57</h1>
    <div>    <div class="entities" style="line-height: 2.5; direction: ltr">
        <h2>Query:</h2>
            <mark class="entity" style="background: linear-gradient(60deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">interacts_with DB06777?</mark>
    
        
<!--        <mark class="entity" style="background: linear-gradient(60deg, #f08080, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">instance_of a familiar path</mark>-->
    <h2>Candidates: </h2>
            <mark class="entity" style="background: linear-gradient(60deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">DB00207<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">#0</span></mark>

    
            <mark class="entity" style="background: linear-gradient(60deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">DB00222<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">#1</span></mark>

    
            <mark class="entity" style="background: linear-gradient(60deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">DB00294<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">#2</span></mark>

    
            <mark class="entity" style="background: linear-gradient(60deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">DB00382<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">#3</span></mark>

    
            <mark class="entity" style="background: linear-gradient(60deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">DB00712<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">#4</span></mark>

    
            <mark class="entity" style="background: linear-gradient(60deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">DB00783<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">#5</span></mark>

    
            <mark class="entity" style="background: linear-gradient(60deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">DB00912<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">#6</span></mark>

    
            <mark class="entity" style="background: linear-gradient(60deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">DB04844<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">#7</span></mark>

    
            <mark class="entity" style="background: linear-gradient(60deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">DB06822<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">#8</span></mark>

    
<!--        <mark class="entity" style="background: linear-gradient(60deg, #addeee, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">album<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">#0</span></mark>-->

        <h2>Answer: </h2>
            <mark class="entity" style="background: linear-gradient(60deg, #860019, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">DB00783</mark>

    
<!--        <mark class="entity" style="background: linear-gradient(60deg, #fff68f, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">album -> instance_of a familiar path</mark>-->




<!--        <mark class="entity" style="background: linear-gradient(60deg, #acaeea, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">likely, single<span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">#0</span></mark>-->
    <h2>Graph:</h2>
    <img height="500" src="data:image/jpeg;base64,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" />
    <h2>Model Output:</h2>
    <table class="gridtable">
<tr><th>Score</th><th>DB00207</th><th>DB00222</th><th>DB00294</th><th>DB00382</th><th>DB00712</th><th>DB00783</th><th>DB00912</th><th>DB04844</th><th>DB06822</th></tr><tr><td>Men.</td><td>0.03596412017941475</td><td>0.21718284487724304</td><td>0.06414442509412766</td><td>0.0030318850185722113</td><td>0.08315809071063995</td><td>0.27211591601371765</td><td>0.21631763875484467</td><td>0.06019673869013786</td><td>0.04788829758763313</td></tr><tr><td>Men. Rank</td><td>7</td><td>1</td><td>4</td><td>8</td><td>3</td><td>0</td><td>2</td><td>5</td><td>6</td></tr><tr><td>Can.</td><td>0.05356922745704651</td><td>0.12380240112543106</td><td>0.05085619539022446</td><td>0.00042681684135459363</td><td>0.15342694520950317</td><td>0.12209302186965942</td><td>0.13314206898212433</td><td>0.053693220019340515</td><td>0.30899015069007874</td></tr><tr><td>Can. Rank</td><td>6</td><td>3</td><td>7</td><td>8</td><td>1</td><td>4</td><td>2</td><td>5</td><td>0</td></tr><tr><td>Sum</td><td>0.08953334391117096</td><td>0.3409852385520935</td><td>0.11500062048435211</td><td>0.0034587017726153135</td><td>0.23658503592014313</td><td>0.3942089378833771</td><td>0.349459707736969</td><td>0.11388996243476868</td><td>0.35687845945358276</td></tr><tr><td>Sum Rank</td><td>7</td><td>3</td><td>5</td><td>8</td><td>4</td><td>0</td><td>2</td><td>6</td><td>1</td></tr>
    </table>
    </div></div><br/><br/><br/><h2 style="margin: 0">0</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Stimulation of epithelial repair is a likely mechanism for the action of mifepristone in reducing duration of bleeding in users of progestogen-only contraceptives . Many women using progestogen ( P ) - only contraceptives experience uterine bleeding problems . In clinical trials , a single low dose of mifepristone , given to 
<mark class="entity" style="background: linear-gradient(90deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB00294
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">MEN</span>
</mark>
 users at the beginning of a bleeding episode reduced the number of bleeding days by approximately 50 % compared with controls . In this study , a single dose of mifepristone was administered to etonogestrel ( P17813 ) - exposed pseudo-pregnant mice , 5 days after artificial decidualization was induced when the endometrium showed signs of bleeding . Control mice received vehicle alone . Mice were culled 12 - , 18 - , 24 - and 48 - h post-treatment . In the continued presence of P17813 , a single dose of mifepristone stimulated tissue breakdown followed by very rapid repair : most treated tissues were fully restored to the pre-decidualized state by 48 h post-treatment . During repair , proliferating cells ( Ki67 immunostained ) were localized to a band of cells around the basal area in breaking down tissues and to the repairing luminal epithelium and glands . P06401 - positive cells were largely localized to the basal area of the breaking down tissue in treated mice compared with decidual cells in controls . Oestrogen receptor-positive cells were observed in the repairing luminal epithelium and glands compared with the decidua and the basal region in control tissues . It is concluded that mifepristone treatment stimulates rapid restoration of luminal epithelial integrity : such action may be a key event in reducing the number of bleeding days observed in women using 
<mark class="entity" style="background: linear-gradient(90deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB00294
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">MEN</span>
</mark>
 who were treated with a single dose of mifepristone .</div>

<h2 style="margin: 0">1</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha - hydroxylase gene expression . Mouse fibroblast growth factor 15 ( FGF 15 ) and human ortholog O95750 have been identified as the bile acid-induced intestinal factors that mediate bile acid feedback inhibition of cholesterol 7alpha - hydroxylase gene ( C YP7A1 ) transcription in mouse liver . The mechanism underlying FGF 15 / O95750 inhibition of bile acid synthesis in hepatocytes remains unclear . Chenodeoxycholic acid ( 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 ) and the farnesoid X receptor ( Q96RI1 ) - specific agonist GW4064 strongly induced O95750 but inhibited P22680 messenger RNA ( mRNA ) levels in primary human hepatocytes . O95750 strongly and rapidly repressed P22680 but not small heterodimer partner ( Q15466 ) mRNA levels . Kinase inhibition and phosphorylation assays revealed that the mitogen-activated protein kinase / extracellular signal-regulated kinase 1/2 ( MAPK / Erk 1/2 ) pathway played a major role in mediating O95750 inhibition of P22680 . However , small interfering RNA ( siRNA ) knockdown of Q15466 did not affect O95750 inhibition of P22680 . Interestingly , 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 stimulated tyrosine phosphorylation of the FGF receptor 4 ( P22455 ) in hepatocytes . O95750 antibody and siRNA specific to P22455 abrogated GW4064 inhibition of P22680 . These results suggest that bile acid-activated Q96RI1 is able to induce O95750 in hepatocytes to inhibit P22680 by an autocrine / paracrine mechanism . CONCLUSION : The hepatic O95750 / P22455 / Erk 1/2 pathway may inhibit P22680 independent of Q15466 . In addition to inducing O95750 in the intestine , bile acids in hepatocytes may activate the liver O95750 / P22455 signaling pathway to inhibit bile acid synthesis and prevent accumulation of toxic bile acid in human livers .</div>

<h2 style="margin: 0">2</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Heymann antibodies induce complement-dependent injury of rat glomerular visceral epithelial cells . The aim of this study was to investigate the in vitro role of the complement membrane attack complex ( MAC ) in the injury induced by nephritogenic anti-brush border vesicle ( Fx1A ) antibodies on rat glomerular visceral epithelial cells ( GEC ) . Both sheep and rabbit anti-rat brush border vesicle IgG-induced complement-dependent lysis of cultured GEC . Fab fragments of sheep anti-rat brush border vesicles and polyclonal or monoclonal P98164 IgG were devoid of lytic activity . Shedding of cell-surface antigens induced by sheep or rabbit anti-rat brush border vesicle IgG protected GEC from subsequent exposure to lytic antibodies and complement , an effect that was not obtained with Fab fragments . When GEC were incubated with sheep or rabbit anti-rat brush border vesicle IgG in capping conditions , the P01024 component was co-redistributed with Heymann immune complexes ; in contrast , the MAC remained diffusely bound to the cell surface , indicating that it was not associated with the antigen-antibody complexes . The MAC was demonstrated on the surface of GEC by immunofluorescence staining with anti-MAC neoantigen and by electron microscopy of negatively stained membranes showing focal clusters of 110 A MAC lesions . When GEC were treated with sheep IgG or rabbit IgG plus P13671 - deficient sera , the cells were not lysed and MAC was not demonstrable on the surface ; however , lytic activity was restored when P13671 - deficient sera were reconstituted with purified P13671 . The results are consistent with the interpretation that injury induced by Heymann antibodies on GEC is MAC-dependent .</div>

<h2 style="margin: 0">3</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Molecular dissection of dimethylnitrosamine ( O15061 ) - induced hepatotoxicity by mRNA differential display . Differential display reverse transcription-polymerase chain reaction ( DDRT-PCR ) was used to catalogue altered hepatic transcript expression during dimethylnitrosamine ( O15061 ) exposure in vivo . Mice were administered O15061 ( 1.5 or 5 mg / kg ) or vehicle ( phosphate-buffered saline ) i . p . once daily for up to 7 days , and livers were collected 6 h post-injection . Total RNA was reverse transcribed and cDNA subsets were selectively amplified by PCR . DDRT-PCR products were fractionated on denaturing polyacrylamide gels , and differentially expressed bands were excised , reamplified , and subsequently cloned into a plasmid vector . This study identified 23 cDNAs that were induced and 25 cDNAs that were suppressed during O15061 exposure . Altered expression during O15061 exposure for cDNA clones was confirmed by Northern blotting , RNase protection , or in situ hybridization analyses . DNA sequence information indicated that four cDNAs suppressed during O15061 exposure encode cytochrome P450 isoenzyme-cholesterol 7 alpha-hydroxylase ( P22680 ) , a monokine , a myeloid cell differentiation protein , and mouse major urinary protein ( MUP ) . We further observed a O15061 - induced increase in transcripts for complement factor 3 ( P01024 ) and serum amyloid A ( P0DJI8 ) . In contrast , the remaining differentially expressed transcripts detected by DDRT-PCR during O15061 exposure demonstrated no similarity to sequences present in Genbank , suggesting that they may encode previously unreported gene products . In situ hybridization showed MUP transcripts to be expressed by hepatic centrilobular areas that undergo necrosis during subchronic O15061 exposure . Thus , the utilization of DDRT-PCR has identified several differentially expressed hepatic mRNAs associated with various doses and stages of O15061 exposure .</div>

<h2 style="margin: 0">4</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Protection of lung epithelial cells from protease-mediated injury by trappin - 2 A62L , an engineered inhibitor of neutrophil serine proteases . Neutrophil serine proteases ( NSPs ) , including elastase , proteinase 3 and cathepsin G , play critical roles in the pathogenesis of chronic inflammatory lung diseases . The release of excess NSPs leads to the destruction of lung tissue and an overexuberant , sustained inflammatory response . Antiproteases could be valuable tools for controlling these NSP-mediated inflammatory events . We have examined the capacity of trappin - 2 A62L , a potent engineered inhibitor of all three NSPs , to protect human lung A549 epithelial cells from the deleterious effects of NSPs . Trappin - 2 A62L , significantly inhibited the detachment of A549 cells and the degradation of the tight-junction proteins , P12830 , β-catenin and ZO - 1 , induced by each individual NSP and by activated neutrophils . Trappin - 2 A62L also decreased the release of the pro-inflammatory cytokines P05231 and P10145 from A549 cells that had been stimulated with elastase or LPS . Trappin - 2 A62D / M63L , a trappin - 2 variant that has no antiprotease activity , has similar properties , suggesting that the anti-inflammatory action of trappin - 2 is independent of its antiprotease activity . Interestingly , we present evidence that trappin - 2 A62L , as well as wild-type trappin - 2 , enter A549 cells and move rapidly to the cytoplasm and nucleus , where they are likely to exert their anti-inflammatory effects . We have also demonstrated that trappin - 2 A62L inhibits the early apoptosis of A549 cells mediated by NSPs . Thus , our data indicate that trappin - 2 A62L is a powerful anti-protease and anti-inflammatory agent that could be used to develop a treatment for patients with inflammatory lung diseases .</div>

<h2 style="margin: 0">5</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Activation of c-Jun-N-terminal-kinase is crucial for the induction of a cell cycle arrest in human colon carcinoma cells caused by flurbiprofen enantiomers . The unselective cyclooxygenase ( P36551 ) inhibitor 
<mark class="entity" style="background: linear-gradient(90deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB00712
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">MEN</span>
</mark>
 and its-in terms of P36551 - inhibition - &quot; inactive &quot; enantiomer R-flurbiprofen have been previously found to inhibit tumor development and growth in various animal models . The underlying mechanisms are unknown . Here , we show that both R - and 
<mark class="entity" style="background: linear-gradient(90deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB00712
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">MEN</span>
</mark>
 reduce survival of three colon cancer cell lines , which differ in the expression of P35354 ( HCT - 15 , no P35354 ; Caco - 2 , inducible P35354 ; and HT - 29 , constitutive P35354 ) . The IC50 for S - and R-flurbiprofen ranged from 250 to 450 microM . Both flurbiprofen enantiomers induced apoptosis in all three cell lines as indicated by DNA - and PARP-cleavage . In addition , R - and 
<mark class="entity" style="background: linear-gradient(90deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB00712
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">MEN</span>
</mark>
 caused a P55008 - cell cycle block . The latter was associated with an activation of c-Jun N-terminal kinase ( JNK ) , an increase of the DNA binding activity of the transcription factor AP - 1 and down-regulation of cyclin D1 expression . Western blot analysis , as well as supershift experiments , revealed that the AP - 1 activation was associated with a change of AP - 1 composition toward an increase of JunB . The JNK inhibitor SP600125 antagonized R - and 
<mark class="entity" style="background: linear-gradient(90deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB00712
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">MEN</span>
</mark>
 - induced AP - 1 DNA binding , suppression of cyclin D1 expression , and the P55008 - cell cycle block . However , JNK inhibition had no effect on flurbiprofen-induced apoptosis . Hence , the cell cycle arrest is obviously mediated , at least in part , through JNK-activation , whereas R - and 
<mark class="entity" style="background: linear-gradient(90deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB00712
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">MEN</span>
</mark>
 - induced apoptosis is largely independent of JNK . Although in vitro effects of R - and 
<mark class="entity" style="background: linear-gradient(90deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB00712
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">MEN</span>
</mark>
 were indistinguishable , only R-flurbiprofen inhibited HCT - 15 tumor growth in nude mice , suggesting the involvement of additional in vivo targets , which are differently affected by R - and 
<mark class="entity" style="background: linear-gradient(90deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB00712
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">MEN</span>
</mark>
 .</div>

<h2 style="margin: 0">6</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Bile acid-induced negative feedback regulation of the human ileal bile acid transporter . Ileal expression of the apical sodium-dependent bile acid transporter ( Q12908 ) in the rat is unaffected by bile salts , yet in the mouse it is under negative-feedback regulation . The bile acid responsiveness of human Q12908 is unknown . The human Q12908 promoter linked to a luciferase reporter was studied in Caco - 2 cells treated with chenodeoxycholic acid ( 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 ) and transfected with expression plasmids for farnesoid Q9UBH6 ( Q96RI1 ) , short heterodimer partner ( Q15466 ) , and retinoic acid receptor / retinoid X receptor ( RAR / RXR ) . 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 treatment of Caco - 2 cells led to a 75 % reduction in steady-state Q12908 messenger RNA levels and a 78 % reduction in human Q12908 promoter activity . A dominant negative Q96RI1 abrogated the response to 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 . Site-directed mutagenesis of an RAR / RXR cis element in the human Q12908 promoter reduced its activity by 50 % and eliminated the bile acid response . Retinoic acid activated the human Q12908 promoter fourfold . Q15466 repressed the activity of the Q12908 promoter and reduced activation by retinoic acid . Antisense mediated knock-down of Q15466 in Caco - 2 cells partially offset the bile acid mediated repression of Q12908 promoter activity . In conclusion , the human Q12908 is positively regulated by retinoic acid . Bile acids induce a negative feedback regulation of human Q12908 via an Q96RI1 - mediated , Q15466 - dependent effect upon RAR / RXR activation of Q12908 .</div>

<h2 style="margin: 0">7</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Oleanolic acid is a selective farnesoid X receptor modulator . Oleanolic acid ( OA ) is an ingredient found in some Traditional Chinese Medicine remedies for treating liver ailments . Bile acid biosynthesis and catabolism are in part controlled in the liver by transcription factor farnesoid X receptor ( Q96RI1 ) . It was hypothesized that OA may act through Q96RI1 to mediate some of its beneficial health effects . In this study , it was found that OA bound to the ligand binding domain ( LBD ) of Q96RI1 and blocked its ability to interact with coactivator Q9Y6Q9 . OA also dose-dependently suppressed the activity of Q96RI1 - LBD induced by its endogenous ligand chenodoxycholic acid ( 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 ) . Consistently , OA partially blocked the ability of 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 to induce a Q96RI1 target gene bile salt export protein ( O95342 ) . On the other hand , OA did not affect the expression of another Q96RI1 target gene organic solute transporter ( Q86UW2 ) . Intriguingly , OA modestly enhanced the expression of a third Q96RI1 target gene short heterodimer partner ( Q15466 ) . This evidence collectively suggested that OA acts as a gene selective modulator of Q96RI1 .</div>

<h2 style="margin: 0">8</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Effect of milk hydrolysates on inflammation markers and drug-induced transcriptional alterations in cell-based models . Nonsteroidal anti-inflammatory drugs ( NSAID ) are associated with gastrointestinal inflammation and subsequent damage to the intestinal tissue . Earlier studies in our laboratory have found that specific casein hydrolysates ( CH ) might be useful in the treatment of gastrointestinal wounds . The underlying mechanisms that support inflammation and wound healing are not completely understood , but transcriptional alterations may be used as markers for inflammation and wound healing . The bioactivity of 3 CH prepared by treatment of commercial casein with pepsin ( 60 min ) followed by corolase ( 0 , 10 , or 60 min ) were investigated in intestinal epithelial cells treated with the NSAID indomethacin . The bioactivity was evaluated as transcriptional alterations of transforming growth factor-β 1 ( TGF-β 1 ) , cyclooxygenase - 2 ( P35354 ) , peroxisome proliferator-activated receptor-γ ( Q07869 - γ ) and nuclear factor κB ( NFκB ) by real-time PCR . Furthermore , the effect of CH on lipopolysaccharide-induced inflammation was evaluated in macrophages by measuring PG E ( 2 ) levels . Casein hydrolysates treated with corolase for 10 or 60 min after pepsin treatment downregulated transcription of TGF-β 1 and NFκB ( P &lt; 0.05 ) compared with the hydrolysate treated with pepsin only . Hydrolysate prepared by corolase treatment for 60 min after pepsin hydrolysis downregulated transcription of P35354 ( P &lt; 0.05 ) compared with hydrolysate treated with corolase for only 10 min whereas transcription of Q07869 - γ was not affected ( P &gt; 0.05 ) . Additionally , the hydrolysate prepared by pepsin treatment only ( 0 min corolase ) had a pro-inflammatory effect on macrophages via PG E ( 2 ) stimulation ( P &lt; 0.05 ) . In conclusion , CH produced by a combination of pepsin and corolase treatments downregulated the transcription levels of TGF-β 1 , P35354 , and NFκB .</div>

<h2 style="margin: 0">9</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Identification of a transcriptionally active peroxisome proliferator-activated receptor alpha - interacting cofactor complex in rat liver and characterization of Q9BYK8 as a coactivator . Q07869 ( Q07869 alpha ) plays a central role in the cell-specific pleiotropic responses induced by structurally diverse synthetic chemicals designated as peroxisome proliferators . Transcriptional regulation by liganded nuclear receptors involves the participation of cofactors that form multiprotein complexes to achieve cell - and gene-specific transcription . Here we report the identification of such a transcriptionally active Q07869 alpha-interacting cofactor ( PRIC ) complex from rat liver nuclear extracts that interacts with full-length Q07869 alpha in the presence of ciprofibrate , a synthetic ligand , and leukotriene B ( 4 ) , a natural ligand . The liganded Q07869 alpha-PRIC complex enhanced transcription from a peroxisomal enoyl - DB01992 hydratase / l - 3 - hydroxyacyl - DB01992 dehydrogenase bifunctional enzyme gene promoter template that contains peroxisome proliferator response elements . Rat liver PRIC complex comprises some 25 polypeptides , and their identities were established by mass spectrometry and limited sequence analysis . Eighteen of these peptides contain one or more LXXLL motifs necessary for interacting with nuclear receptors . PRIC complex includes known coactivators or coactivator-binding proteins ( CBP , Q15788 , PBP , PRIP , PIMT , O75448 , Q09428 - 2 , and P20142 - 1 ) , other proteins that have not previously been described in association with transcription complexes ( CHD 5 , TOG , and Q8WYB5 ) , and a few novel polypeptides designated PRIC 300 , - 285 , - 215 , - 177 , and - 145 . We describe the cDNA for Q9BYK8 , which contains five LXXLL motifs . It interacts with Q07869 alpha and acts as a coactivator by moderately stimulating Q07869 alpha-mediated transcription in transfected cells . We conclude that liganded Q07869 alpha recruits a distinctive multiprotein complex from rat liver nuclear extracts . The composition of this complex may provide insight into the basis of tissue and species sensitivity to peroxisome proliferators .</div>

<h2 style="margin: 0">10</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Sesquiterpenoids from Atractylodes macrocephala act as farnesoid X receptor and progesterone receptor modulators . Two sesquiterpenoids , atractylenolide II and III , were isolated and identified from Atractylodes macrocephala ( Asteraceae ) to be subsequently evaluated for their activity against farnesoid X receptor ( Q96RI1 ) and progesterone receptor ( PR ) by transient transfection reporter assays . These sesquiterpenoids did not exert significant agonistic effect but antagonized the activity of chenodeoxycholic acid ( 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 ) , an endogenous Q96RI1 agonist , for Q96RI1 driven Q15466 promoter transactivation . Additionally , they transactivated P22680 gene promoter activity by antagonizing Q96RI1 . Apart from acting as a Q96RI1 antagonist , atractylenolide III also showed agonistic activity against PR . All these results demonstrated that atractylenolide II and III are the active components of Atractylodes macrocephala to exert specific pharmacologic effects .</div>

<h2 style="margin: 0">11</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">New perspectives of vesicular monoamine transporter 2 chemical characteristics in mammals and its constant expression in type 1 diabetes rat models . Vesicular monoamine transporter 2 ( Q05940 ) has been exploited as a biomarker of β-cell mass in human islets . However , a current report suggested no immunoreactivity of Q05940 in the β cells of rat islets . To investigate the cellular localization of Q05940 in islets further , the pancreatic tissues from monkeys and humans were compared with those of rats and mice . The study was performed using among-species comparisons and a type 1 diabetes model ( T1DM ) for rats by Western blotting , double-label immunofluorescence , and confocal laser scanning microscopy . We found that Q05940 - immunoreactivity ( IR ) was distributed peripherally in the islets of rodents , but was widely scattered throughout the islets of primates . Consistent with rodent islets , Q05940 - IR did not exist in insulin ( P01308 ) - IR cells but was abundantly present in glucagon ( GLU ) - IR and pancreatic polypeptide ( PP ) - IR cells in monkey and human islets . Q05940 - IR had no colocalization with P01308 - IR in any part of the rat pancreas ( head , body , and tail ) . P01308 - IR cells were reduced dramatically in T1DM rat islets , but no significant alteration in the proportion of Q05940 - IR cells and GLU-IR cells was observed . Furthermore , a strong colocalization of Q05940 - IR with GLU-IR was distributed in the peripheral regions of diabetic islets . For the first time , the current study demonstrates the presence of Q05940 in α cells and PP cells but not in β cells in the islets of monkeys and humans . This study provides convinced morphologic evidence that Q05940 is not present in β cells . There needs to be studies for new markers for β cell mass .</div>

<h2 style="margin: 0">12</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">DB00877 unbalances the polarization of human macrophages to M1 . Plasticity is a hallmark of macrophages , and in response to environmental signals these cells undergo different forms of polarized activation , the extremes of which are called classic ( M1 ) and alternative ( M2 ) . DB00877 ( Q96PN7 ) is crucial for survival and functions of myeloid phagocytes , but its effects on macrophage polarization are not yet studied . To address this issue , human macrophages obtained from six normal blood donors were polarized to M1 or M2 in vitro by lipopolysaccharide plus interferon-γ or interleukin - 4 ( P05112 ) , respectively . The presence of Q96PN7 ( 10 ng / ml ) induced macrophage apoptosis in M2 but not in M1 . Beyond the impact on survival in M2 , Q96PN7 reduced P61073 , CD206 and Q9NNX6 expression and stem cell growth factor-β , P55774 and Q99616 release . In contrast , in M1 Q96PN7 increased P42081 and P32248 expression and P05231 , tumour necrosis factor-α and IL - 1β release but reduced CD206 and Q9NNX6 expression and P22301 , vascular endothelial growth factor and P55774 release . In view of the in vitro data , we examined the in vivo effect of Q96PN7 monotherapy ( 0 · 1 mg / kg / day ) in 12 patients who were treated for at least 1 month before islet transplant . Cytokine release by O00206 - stimulated peripheral blood mononuclear cells showed a clear shift to an M1 - like profile . Moreover , macrophage polarization 21 days after treatment showed a significant quantitative shift to M1 . These results suggest a role of mammalian target of rapamycin ( P42345 ) into the molecular mechanisms of macrophage polarization and propose new therapeutic strategies for human M2 - related diseases through P42345 inhibitor treatment .</div>

<h2 style="margin: 0">13</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Activation of P00533 promotes squamous carcinoma SCC 10A cell migration and invasion via inducing EMT-like phenotype change and P14780 - mediated degradation of P12830 . P00533 is a potent stimulator of invasion and metastasis in head and neck squamous cell carcinomas ( HNSCC ) . However , the mechanism by which P00533 may stimulate tumor cell invasion and metastasis still need to be elucidated . In this study , we showed that activation of P00533 by P01133 in HNSCC cell line SCC 10A enhanced cell migration and invasion , and induced loss of epitheloid phenotype in parallel with downregulation of P12830 and upregulation of P19022 and vimentin , indicating that P00533 promoted SCC 10A cell migration and invasion possibly by an epithelial to mesenchymal transition ( EMT ) - like phenotype change . Interestingly , activation of P00533 by P01133 induced production of matrix metalloproteinase - 9 ( P14780 ) and soluble P12830 ( sE-cad ) , and knockdown of P14780 by siRNA inhibited sE-cad production induced by P01133 in SCC 10A . Moreover , both P14780 knockdown and P12830 overexpression inhibited cell migration and invasion induced by P01133 in SCC 10A . The results indicate that P00533 activation promoted cell migration and invasion through inducing P14780 - mediated degradation of P12830 into sE-cad . Pharmacologic inhibition of P00533 , MEK , and PI3K kinase activity in SCC 10A reduced phosphorylated levels of P27361 / 2 and AKT , production of P14780 and sE-cad , cell migration and invasion , and expressional changes of EMT markers ( P12830 and P19022 ) induced by P01133 , indicating that P00533 activation promotes cell migration and invasion via P27361 / 2 and PI3K - regulated P14780 / P12830 signaling pathways . Taken together , the data suggest that P00533 activation promotes HNSCC SCC 10A cell migration and invasion by inducing EMT-like phenotype change and P14780 - mediated degradation of P12830 into sE-cad related to activation of P27361 / 2 and PI3K signaling pathways .</div>

<h2 style="margin: 0">14</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Feedback regulation of bile acid synthesis in human liver : importance of HNF - 4alpha for regulation of P22680 . A great number of nuclear factors are involved in the negative feedback mechanism regulating bile acid synthesis . There are two major ways for the negative feedback to effect the synthesis ; the Q15466 - dependent , involving Q96RI1 , and the Q15466 - independent way , affecting HNF - 4alpha . We studied 23 patients with gallstone disease . Eight patients were treated with chenodeoxycholic acid , 7 with cholestyramine prior to operation , and 8 served as controls . Liver biopsies were analyzed with Real-time-PCR . In the cholestyramine-treated group mRNA levels of P22680 were increased about 10 - fold . Treatment with 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 decreased the mRNA levels of P22680 by about 70 % . The mRNA levels of Q9UNU6 , Q02318 , and O75881 were not significantly altered in the treated groups . The analysis of mRNA levels for HNF - 4alpha showed 64 % higher levels in the cholestyramine-treated group compared to the controls . These levels showed positive and highly significant correlation to the levels of mRNA of P22680 when studied in all three groups together . Q96RI1 , Q15466 , and O00482 / O00482 were not significantly affected by the different treatments . Our results indicate that when bile acid synthesis is upregulated by cholestyramine treatment the Q15466 - independent pathway for controlling P22680 transcription dominates over the Q15466 - dependent pathway .</div>

<h2 style="margin: 0">15</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">MGC 9753 gene , located within Q9UD71 - Q14849 - P04626 - Q14451 amplicon on human chromosome 17q12 , encodes the seven-transmembrane receptor with extracellular six-cystein domain . MYC , P04626 , MET , P21802 , P24864 , P04198 , P09544 , P16070 , Q00987 , Q9Y6Q9 , P46940 and O14965 loci are amplified in human gastric cancer . It has been reported that the gene corresponding to EST H16094 is co-amplified with P04626 gene in human gastric cancer . Here , we identified and characterized the gene corresponding to EST H16094 by using bioinformatics . BLAST programs revealed that EST H16094 was derived from the uncharacterized MGC 9753 gene . Two ORFs were predicted within human MGC 9753 mRNA , and ORF 1 ( nucleotide position 18-980 of NM_033419 . 1 ) was predicted as the coding region of human MGC 9753 mRNA based on comparative genomics . Nucleotide sequence of mouse Mgc 9753 mRNA was next determined in silico by modification of AK052486 cDNA ( deleting C at the nucleotide position 37 ) . Human MGC 9753 and mouse Mgc 9753 proteins were 320 - amino-acid seven-transmembrane receptors with the N-terminal six-cysteine domain and an N-glycosylation site ( 85.0 % total-amino-acid identity ) . Human MGC 9753 protein showed 90.6 % total-amino-acid identity with human CAB 2 aberrant protein , which lacked the third-transmembrane domain of MGC 9753 due to frame shifts within ORF . Human MGC 9753 gene , consisting of eight exons , were clustered with Q9UD71 , Q14849 , O15273 , PNMT , P04626 , MGC 14832 and Q14451 genes within the 120 - kb region . Q9UD71 , Q14849 , MGC 9753 , P04626 and Q14451 genes are co-amplified in several cases of gastric cancer . This is the first report on comprehensive characterization of the amplicon around the Q9UD71 - Q14849 - O15273 - PNMT-MGC 9753 - P04626 - MGC 14832 - Q14451 locus on human chromosome 17q12 .</div>

<h2 style="margin: 0">16</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and nonneoplastic tissues . OBJECTIVES : The aim of this study was to evaluate transcript levels of all 49 human DB00171 - binding cassette transporters ( ABCs ) in one of the most drug-resistant cancers , namely , the pancreatic ductal adenocarcinoma ( PDAC ) . Association of ABCs levels with clinical-pathologic characteristics and P01116 mutation status was followed as well . METHODS : Tumors and adjacent nonneoplastic tissues were obtained from 32 histologically verified PDAC patients . The transcript profile of ABCs was assessed using quantitative real-time polymerase chain reaction with a relative standard curve . P01116 mutations in exon 2 were assessed by high-resolution melting analysis and sequencing . RESULTS : Most ABCs were deregulated in PDAC and 10 ABCs were associated with clinical-pathologic characteristics . P01116 mutations did not change the global expression profile of ABCs . CONCLUSIONS : The expression of ABC transporters was significantly deregulated in PDAC tumors when compared to nonmalignant tissues . The observed up-regulation of P21439 , O95342 , P33527 , O15438 , O15440 , Q5T3U5 , and Q9UNQ0 in tumors may contribute to the generally poor treatment response of PDAC . The up-regulation of O95477 , Q8IZY2 , and P45844 implicates a serious impairment of cellular cholesterol homeostasis in PDAC . On the other hand , the observed down-regulation of Q99758 , O95255 , P13569 , and Q09428 suggests a possible role of stem cells in the development and progression of PDAC .</div>

<h2 style="margin: 0">17</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Activation of the farnesoid X receptor represses Q8NBP7 expression in human hepatocytes . The purpose of this study was to determine whether bile acids ( BAs ) modulate hepatic pro-protein convertase subtilisin / kexin 9 ( Q8NBP7 ) gene expression . Immortalized human hepatocytes were treated with various BAs . Chenodeoxycholic acid ( 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 ) treatment specifically decreased both Q8NBP7 mRNA and protein contents . Moreover , activation of the BA-activated farnesoid X receptor ( Q96RI1 ) by its synthetic specific agonist GW4064 also decreased Q8NBP7 expression . Of functional relevance , coadministration of 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 counteracted the statin-induced Q8NBP7 expression , leading to a potentiation of P01130 activity . This study suggests that a transcriptional repression of Q8NBP7 by 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 or Q96RI1 agonists may potentiate the hypolipidemic effect of statins .</div>

<h2 style="margin: 0">18</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">The unexpected effect of cyclosporin A on CD56 + CD16 - and CD56 + CD16 + natural killer cell subpopulations . DB00091 ( Q13216 ) is commonly used to prevent graft-versus-host disease . The influence of Q13216 on T-cell function has been extensively investigated ; however , the effect of Q13216 on natural killer ( NK ) cells is less understood . NK cells were cultured with P60568 and P40933 with and without Q13216 for 1 week . Compared with controls , Q13216 - treated cultures showed fewer CD56 ( + ) CD16 ( + ) P55040 ( + ) NK cells and a reciprocal increase in CD56 ( + ) CD16 ( - ) P55040 ( - ) cells . These changes were due mainly to a reduced proliferation of the CD56 ( dim ) NK-cell subpopulation and a relative resistance of CD56 ( bright ) NK cells to Q13216 . Following coculture with K562 targets , Q13216 - exposed NK cells differed from controls and lacked Ca ( 2 + ) oscillations , nuclear factor of activated T cells ( NFAT ) dephosphorylation , and NFAT nuclear translocation . NK cells cultured in Q13216 retained cytotoxicity against K562 , Raji , and P55040 ligand-expressing lymphoblastoid cells . NK cells cultured in Q13216 showed increases in O14931 and reductions in O95944 and P26718 . Following IL - 12 and Q14116 stimulation , Q13216 - treated NK cells showed more P01579 - producing cells . Using in vitro NK-cell differentiation , progenitor cells gave rise to more CD56 ( + ) P55040 ( - ) NK cells in the presence of Q13216 than controls . Collectively , these studies show that Q13216 influences NK-cell function and phenotype , which may have important implications for graft-versus-leukemia effects .</div>

<h2 style="margin: 0">19</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">All-trans retinoic acid regulates hepatic bile acid homeostasis . Retinoic acid ( RA ) and bile acids share common roles in regulating lipid homeostasis and insulin sensitivity . In addition , the receptor for RA ( retinoid x receptor ) is a permissive partner of the receptor for bile acids , farnesoid x receptor ( Q96RI1 / Q96RI1 ) . Thus , RA can activate the Q96RI1 - mediated pathway as well . The current study was designed to understand the effect of all-trans RA on bile acid homeostasis . Mice were fed an all-trans RA-supplemented diet and the expression of 46 genes that participate in regulating bile acid homeostasis was studied . The data showed that all-trans RA has a profound effect in regulating genes involved in synthesis and transport of bile acids . All-trans RA treatment reduced the gene expression levels of Cyp 7a1 , Cyp 8b1 , and Akr 1d1 , which are involved in bile acid synthesis . All-trans RA also decreased the hepatic mRNA levels of Lrh - 1 ( Nr5a2 ) and Hnf 4α ( Nr2a1 ) , which positively regulate the gene expression of Cyp 7a1 and Cyp 8b1 . Moreover , all-trans RA induced the gene expression levels of negative regulators of bile acid synthesis including hepatic Fgfr 4 , Fxr , and Shp ( Nr0b2 ) as well as ileal Fgf 15 . All-trans RA also decreased the expression of Abcb 11 and Slc 51b , which have a role in bile acid transport . Consistently , all-trans RA reduced hepatic bile acid levels and the ratio of CA / 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 , as demonstrated by liquid chromatography-mass spectrometry . The data suggest that all-trans RA-induced Q15466 may contribute to the inhibition of P22680 and Q9UNU6 , which in turn reduces bile acid synthesis and affects lipid absorption in the gastrointestinal tract .</div>

<h2 style="margin: 0">20</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Genome-wide association study identifies O95150 and Q16633 as susceptibility loci for primary biliary cirrhosis in the Japanese population . For the identification of susceptibility loci for primary biliary cirrhosis ( P10515 ) , a genome-wide association study ( GWAS ) was performed in 963 Japanese individuals ( 487 P10515 cases and 476 healthy controls ) and in a subsequent replication study that included 1,402 other Japanese individuals ( 787 cases and 615 controls ) . In addition to the most significant susceptibility region , human leukocyte antigen ( HLA ) , we identified two significant susceptibility loci , O95150 ( rs4979462 ) and Q16633 ( rs4938534 ) ( combined odds ratio [ OR ] = 1.56 , p = 2.84 × 10 ( - 14 ) for rs4979462 , and combined OR = 1.39 , p = 2.38 × 10 (-8 ) for rs4938534 ) . Among 21 non-HLA susceptibility loci for P10515 identified in GWASs of individuals of European descent , three loci ( P16871 , Q9UKT9 , and P33681 ) showed significant associations ( combined p = 3.66 × 10 (-8 ) , 3.66 × 10 ( - 9 ) , and 3.04 × 10 ( - 9 ) , respectively ) and Q14765 and P19838 loci showed suggestive association with P10515 ( combined p = 1.11 × 10 ( - 6 ) and 1.42 × 10 ( - 7 ) , respectively ) in the Japanese population . These observations indicated the existence of ethnic differences in genetic susceptibility loci to P10515 and the importance of P01375 signaling and B cell differentiation for the development of P10515 in individuals of European descent and Japanese individuals .</div>

<h2 style="margin: 0">21</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Characterization of lipid metabolism in insulin-sensitive adipocytes differentiated from immortalized human DB05914 . There is a great demand for cell models to study human adipocyte function . Here we describe the adipogenic differentiation of a telomerase-immortalized human mesenchymal stem cell line ( hMSC-Tert ) that maintains numerous features of terminally differentiated adipocytes even after prolonged withdrawal of the peroxisome proliferator activated receptor gamma ( PPARgamma ) agonist rosiglitazone . Differentiated hMSC-Tert developed the characteristic monolocular phenotype of mature adipocytes . The expression of adipocyte specific markers was highly increased during differentiation . Most importantly , the presence of the PPARgamma agonist rosiglitazone was not required for the stable expression of lipoprotein lipase , adipocyte fatty acid binding protein and perilipin on mRNA and protein levels . Q15848 expression was post-transcriptionally down-regulated in the absence of rosiglitazone . P01308 sensitivity as measured by insulin-induced phosphorylation of Akt and S6 ribosomal protein was also independent of rosiglitazone . In addition to commonly used adipogenic markers , we investigated further PPARgamma-stimulated proteins with a role in lipid metabolism . We observed an increase of lipoprotein receptor ( P98155 , Q07954 ) and apolipoprotein E expression during differentiation . Despite this increased expression , the receptor-mediated endocytosis of lipoproteins was decreased in differentiated adipocytes , suggesting that these proteins may have an additional function in adipose tissue beyond lipoprotein uptake .</div>

<h2 style="margin: 0">22</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">A novel bile acid-activated vitamin D receptor signaling in human hepatocytes . Vitamin D receptor ( P11473 ) is activated by natural ligands , 1alpha , 25 - dihydroxy-vitamin D ( 3 ) [ 1alpha , 25 ( OH ) ( 2 ) - D ( 3 ) ] and lithocholic acid ( LCA ) . Our previous study shows that P11473 is expressed in human hepatocytes , and P11473 ligands inhibit bile acid synthesis and transcription of the gene encoding cholesterol 7alpha - hydroxylase ( P22680 ) . Primary human hepatocytes were used to study LCA and 1alpha , 25 ( OH ) ( 2 ) - D ( 3 ) activation of P11473 signaling . Confocal immunofluorescent microscopy imaging and immunoblot analysis showed that LCA and 1alpha , 25 ( OH ) ( 2 ) - D ( 3 ) induced intracellular translocation of P11473 from the cytosol to the nucleus and also plasma membrane where P11473 colocalized with caveolin - 1 . P11473 ligands induced tyrosine phosphorylation of c-Src and P11473 and their interaction . Inhibition of c-Src abrogated P11473 ligand-dependent inhibition of P22680 mRNA expression . Kinase assays showed that P11473 ligands specifically activated the c-Raf / Q02750 / 2 / extracellular signal-regulated kinase ( P29323 ) 1/2 pathway , which stimulates serine phosphorylation of P11473 and hepatocyte nuclear factor - 4alpha , and their interaction . Mammalian two-hybrid assays showed a P11473 ligand-dependent interaction of nuclear receptor corepressor - 1 and silencing mediator of retinoid and thyroid with P11473 / retinoid X receptor-alpha ( RXRalpha ) . Chromatin immunoprecipitation assays revealed that an P27361 / 2 inhibitor reversed P11473 ligand-induced recruitment of P11473 , RXRalpha , and corepressors to human P22680 promoter . In conclusion , P11473 ligands activate membrane P11473 signaling to activate the Q02750 / 2 / P27361 / 2 pathway , which stimulates nuclear P11473 / RXRalpha recruitment of corepressors to inhibit P22680 gene transcription in human hepatocytes . This membrane P11473 - signaling pathway may be activated by bile acids to inhibit bile acid synthesis as a rapid response to protect hepatocytes from cholestatic liver injury .</div>

<h2 style="margin: 0">23</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Interaction of murine peritoneal leukocytes and mesothelial cells : in vitro model system to survey cellular events on serosal membranes during inflammation . All serosal cavities including peritoneum are lined with a simple squamous mesothelium . Primary culture of murine mesothelial cells has been established to study their cellular interactions with peritoneal leukocytes . The mesothelial character was determined by the cytokeratin and vimentin expression . The mesothelial cells expressed P05362 and P16070 molecules . The expression of P05362 , but not P16070 , was significantly enhanced by the treatment with P01375 ( 100 U / ml ) . We have also investigated possible influence of transforming growth factors , TGF-alpha ( 20 ng / ml ) and TGF-beta ( 2 ng / ml ) , and epidermal growth factor ( 20 ng / ml ) . These factors were not found to modulate P05362 or P16070 expression in vitro . During coculture experiments unstimulated mesothelial cells were almost nonadherent for both resident and elicited peritoneal mononuclear leukocytes for several hours . P01375 or P01133 pretreatment of mesothelial cells greatly enhanced their adhesive affinity to peritoneal mononuclear leukocytes , while TGF-beta pretreatment even reduced the low basal adhesion . Prolonged coculture for 3 weeks resulted in remarkable proliferation and differentiation of both resident and elicited monocytes / macrophages on the mesothelial surface . The stimulation of mesothelial cell culture with P01133 resulted in the macrophage colony-stimulating activity ( M - Q13216 ) production . M - Q13216 was mainly due to P09603 as confirmed with anti P09603 monoclonal antibody ; the residual M - Q13216 was not formed by GM - P04141 . After several passages the mesothelial cells started to produce M - Q13216 spontaneously .</div>

<h2 style="margin: 0">24</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Synthesis and evaluation of ( S ) - 2 - ( 2 - [ 18F ] fluoroethoxy ) - 4 - ( [ 3 - methyl - 1 - ( 2 - piperidin - 1 - yl-phenyl ) - butyl-carbamoyl ] - methyl ) - benzoic acid ( [ 18F ] repaglinide ) : a promising radioligand for quantification of pancreatic beta-cell mass with positron emission tomography ( PET ) . 18F - labeled non-sulfonylurea hypoglycemic agent ( S ) - 2 - ( 2 - [ ( 18 ) F ] fluoroethoxy ) - 4 - ( ( 3 - methyl - 1 - ( 2 - piperidin - 1 - yl-phenyl ) - butylcarbamoyl ) - methyl ) - benzoic acid ( [ ( 18 ) F ] repaglinide ) , a derivative of the sulfonylurea-receptor ( Q09428 ) ligand repaglinide , was synthesized as a potential tracer for the non-invasive investigation of the sulfonylurea 1 receptor status of pancreatic beta-cells by positron emission tomography ( PET ) in the context of type 1 and type 2 diabetes . [ ( 18 ) F ] 
<mark class="entity" style="background: linear-gradient(90deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB00912
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">MEN</span>
</mark>
 could be obtained in an overall radiochemical yield ( RCY ) of 20 % after 135 min with a radiochemical purity higher than 98 % applying the secondary labeling precursor 2 - [ ( 18 ) F ] fluoroethyltosylate . Specific activity was in the range of 50-60 GBq / micromol . Labeling was conducted by exchanging the ethoxy-moiety into a 2 - [ ( 18 ) F ] fluoroethoxy group . To characterize the properties of fluorinated repaglinide , the affinity of the analogous non-radioactive ( 19 ) F-compound for binding to the human Q09428 isoform was assessed . [ ( 19 ) F ] 
<mark class="entity" style="background: linear-gradient(90deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB00912
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">MEN</span>
</mark>
 induced a complete monophasic inhibition curve with a Hill coefficient close to 1 ( 1.03 ) yielding a dissociation constant ( K ( D ) ) of 134 nM . Biological activity was proven via insulin secretion experiments on isolated rat islets and was comparable to that of repaglinide . Finally , biodistribution of [ ( 18 ) F ] repaglinide was investigated in rats by measuring the concentration of the compound in different organs after i . v . injection . Pancreatic tissue displayed a stable accumulation of approximately 0.12 % of the injected dose from 10 min to 30 min p . i . 50 % of the radioactive tracer could be displaced by additional injection of unlabeled repaglinide , indicating that [ ( 18 ) F ] repaglinide might be suitable for in vivo investigation with PET .</div>

<h2 style="margin: 0">25</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">The bile acid receptor Q96RI1 is a modulator of intestinal innate immunity . The farnesoid X receptor ( Q96RI1 ) is a bile acid-regulated nuclear receptor expressed in enterohepatic tissues . In this study we investigated whether Q96RI1 is expressed by cells of innate immunity and regulates inflammation in animal models of colitis . Acute ( 7 days ) and chronic ( 8 wk ) colitis were induced in wild-type and Q96RI1 ( - / - ) mice by intrarectal administration of trinitrobenzensulfonic acid or by 7 - day administration of 5 % dextran sulfate in drinking water . The results of this experiment demonstrate that Q96RI1 is expressed by and exerts counterregulatory effects on cells of innate immunity . Exposure of LPS-activated macrophages to 6 - ethyl chenodeoxycholic acid ( 6E - 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 ; INT - 747 ) a synthetic Q96RI1 ligand , results in a reciprocal regulation of NF-kappaB dependent-genes ( P01375 , IL - 1beta , P05231 , P23219 , P35354 , and P35228 ) and induction of Q15466 , a Q96RI1 - regulated gene . Q96RI1 activation stabilizes the nuclear corepressor NCoR on the NF-kappaB responsive element on the IL - 1beta promoter . Colon inflammation in Crohn ' s disease patients and in rodent models of colitis is associated with a reduced expression of Q96RI1 mRNA . Using two rodent models of colon inflammation , we show that progression of these immune-mediated disorders is exacerbated in Q96RI1 ( - / - ) mice ( p &lt; 0.01 ) . In vivo treatment with INT - 747 attenuates organ injury and immune cell activation . Q96RI1 activation increased the colon expression of P51161 , Q96RI1 , and Q15466 while reducing IL - 1beta , P60568 , P05231 , P01375 , and P01579 mRNA expression and attenuating disease severity . In aggregate , these findings provide evidence that Q96RI1 is an essential component of a network of nuclear receptors that regulate intestinal innate immunity and homeostasis .</div>

<h2 style="margin: 0">26</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Involvement of multiple elements in Q96RI1 - mediated transcriptional activation of O95750 . The intestinal endocrine hormone human fibroblast growth factor 19 ( O95750 ) is involved in the regulation of not only hepatic bile acid metabolism but also carbohydrate and lipid metabolism . In the present study , bile acid / farnesoid X receptor ( Q96RI1 ) responsiveness in the O95750 promoter region was investigated by a reporter assay using the human colon carcinoma cell line LS174T . The assay revealed the presence of bile acid / Q96RI1 - responsive elements in the 5 ' - flanking region up to 8.8 kb of O95750 . Deletion analysis indicated that regions from - 1866 to - 1833 , from - 1427 to - 1353 , and from - 75 to + 262 were involved in Q96RI1 responsiveness . Four , four , and two consecutive half-sites of nuclear receptors were observed in the three regions , respectively . An electrophoretic mobility shift assay ( EMSA ) and chromatin immunoprecipitation ( ChIP ) assay revealed Q96RI1 / retinoid X receptor α ( RXRα ) heterodimer binding in these three regions . EMSA and reporter assays using mutated constructs indicated that the nuclear receptor Q9Y2I1 , ER2 , and Q30134 motifs in the 5 ' - flanking region were involved in Q96RI1 responsiveness of O95750 . Lithocholic acid ( LCA ) ( 10 μM ) , chenodeoxycholic acid ( 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 ) ( 10 μM ) , or GW4064 ( 0.1 μM ) treatment increased reporter activity in a construct including the three motifs under Q96RI1 - expressing conditions whereas LCA and not 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 or GW4064 treatment increased the reporter activity under pregnane X receptor ( O75469 ) - expressing conditions . These results suggest that O95750 is transcriptionally activated through multiple Q96RI1 - responsive elements in the promoter region .</div>

<h2 style="margin: 0">27</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">P49675 - related lipid transfer domain protein 5 binds primary bile acids . Steroidogenic acute regulatory-related lipid transfer ( START ) domain proteins are involved in the nonvesicular intracellular transport of lipids and sterols . The P49675 ( P49675 and Q14849 ) and Q96DR4 subfamilies ( Q96DR4 - 6 ) have an internal cavity large enough to accommodate sterols . To provide a deeper understanding on the structural biology of this domain , the binding of sterols to Q9NSY2 , a member of the Q96DR4 subfamily , was monitored . The SAR by NMR [ ( 1 ) H - ( 15 ) N heteronuclear single-quantum coherence ( HSQC ) ] approach , complemented by circular dichroism ( CD ) and isothermal titration calorimetry ( ITC ) , was used . Titration of Q9NSY2 with cholic ( CA ) and chenodeoxycholic acid ( 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 ) , ligands of the farnesoid X receptor ( Q96RI1 ) , leads to drastic perturbation of the ( 1 ) H - ( 15 ) N HSQC spectra and the identification of the residues in contact with those ligands . The most perturbed residues in presence of ligands are lining the internal cavity of the protein . Ka values of 1.8 · 10 - ( 4 ) M ( - 1 ) and 6.3 · 10 ( 4 ) M ( - 1 ) were measured for CA and 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 , respectively . This is the first report of a START domain protein in complex with a sterol ligand . Our original findings indicate that Q9NSY2 may be involved in the transport of bile acids rather than cholesterol .</div>

<h2 style="margin: 0">28</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Translational research in bipolar disorder : emerging insights from genetically based models . Bipolar disorder ( BPD ) is characterized by vulnerability to episodic depression and mania and spontaneous cycling . Because of marked advances in candidate-gene and genome-wide association studies , the list of risk genes for BPD is growing rapidly , creating an unprecedented opportunity to understand the pathophysiology of BPD and to develop novel therapeutics for its treatment . However , genetic findings are associated with major unresolved issues , including whether and how risk variance leads to behavioral abnormalities . Although animal studies are key to resolving these issues , consensus is needed regarding how to define and monitor phenotypes related to mania , depression and mood swing vulnerability in genetically manipulated rodents . In this study we discuss multiple facets of this challenging area , including theoretical considerations , available tests , limitations associated with rodent behavioral modeling and promising molecular-behavioral findings . These include O15516 , glycogen synthase kinase 3beta ( GSK - 3beta ) , glutamate receptor 6 ( Q13002 ) , extracellular signal-regulated kinase - 1 ( P27361 ) , p11 ( or P60903 ) , vesicular monoamine transporter 2 ( Q05940 or Q05940 ) , glucocorticoid receptors ( GRs ) , Bcl - 2 - associated athanogene - 1 ( Q99933 ) and mitochondrial DNA polymerase-gamma ( P54098 ) . Some mutant rodent strains show behavioral clusters or activity patterns that cross-species phenocopy objective / observable facets of mood syndromes , and changes in these clustered behaviors can be used as outcome measures in genetic-behavioral research in BPD .</div>

<h2 style="margin: 0">29</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Chenodeoxycholic acid-mediated activation of the farnesoid X receptor negatively regulates hydroxysteroid sulfotransferase . Hydroxysteroid sulfotransferase catalyzing bile acid sulfation plays an essential role in protection against lithocholic acid ( LCA ) - induced liver toxicity . Hepatic levels of Sult 2a is up to 8 - fold higher in farnesoid X receptor-null mice than in the wild-type mice . Thus , the influence of Q96RI1 ligand ( chenodeoxycholic acid ( 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 ) and LCA ) feeding on hepatic Sult 2a expression was examined in Q96RI1 - null and wild-type mice . Hepatic Sult 2a protein content was elevated in Q96RI1 - null and wild-type mice fed a LCA ( 1 % and 0.5 % ) diet . Treatment with 0.5 % 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 diet decreased hepatic Sult 2a to 20 % of the control in wild-type mice , but increased the content in Q96RI1 - null mice . Liver Sult 2a1 ( St2a4 ) mRNA levels were reduced to 26 % in wild-type mice after feeding of a 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 diet , while no decrease was observed on Sult 2a1 mRNA levels in Q96RI1 - null mice after 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 feeding . A significant inverse relationship ( r ( 2 )= 0.523 ) was found between hepatic Sult 2a protein content and small heterodimer partner ( Q15466 ) mRNA level . Q15149 - mediated increase in Sult 2a protein levels were attenuated by 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 feeding in wild-type mice , but not in Q96RI1 - null mice . Human Q06520 protein and mRNA levels were decreased in HepG 2 cells treated with the Q96RI1 agonists , 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 or GW4064 in dose-dependent manners , although Q15466 mRNA levels were increased . These results suggest that SULT 2A is negatively regulated through 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 - mediated Q96RI1 activation in mice and humans .</div>

<h2 style="margin: 0">30</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">P01298 enhances plasma glucocorticoid concentration in rats : possible role in hypoglycemic stress . The acute bolus intraperitoneal ( i . p . ) administration of pancreatic polypeptide ( PP ) dose-dependently enhanced the plasma concentration of corticosterone ( P10515 ) in hypophysectomized / DB01285 replaced rats , but not that of aldosterone . Minimal and maximal effective doses were 10 ( - 12 ) and 10 ( - 10 ) mol / rat , respectively , and maximal P10515 increase occurred between 60 and 120 min after PP injection . P01308 ( 1 U / kg , i . p . ) evoked a net decrease in the blood glucose concentration , and marked rises in the plasma levels of PP and P10515 , that attained their maximum at 60 and 120 min , respectively . The effects of insulin were annulled by the simultaneous injection of 0.5 mg / kg atropine . The effects of 1 U / kg insulin and 10 ( - 10 ) mol / rat PP on P10515 were not additive ; atropine did not affect P10515 response to PP or PP plus insulin , though annulling that to insulin alone . Taken together these findings suggest that PP plays a physiologic role in the rat as modulator of the adrenal response to the insulin-induced hypoglycemic stress .</div>

<h2 style="margin: 0">31</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Sources contributing to the average extracellular concentration of dopamine in the nucleus accumbens . Mesolimbic dopamine neurons fire in both tonic and phasic modes resulting in detectable extracellular levels of dopamine in the nucleus accumbens ( NAc ) . In the past , different techniques have targeted dopamine levels in the NAc to establish a basal concentration . In this study , we used in vivo fast scan cyclic voltammetry ( FSCV ) in the NAc of awake , freely moving rats . The experiments were primarily designed to capture changes in dopamine caused by phasic firing - that is , the measurement of dopamine ' transients ' . These FSCV measurements revealed for the first time that spontaneous dopamine transients constitute a major component of extracellular dopamine levels in the NAc . A series of experiments were designed to probe regulation of extracellular dopamine . DB00281 was infused into the ventral tegmental area , the site of dopamine cell bodies , to arrest neuronal firing . While there was virtually no instantaneous change in dopamine concentration , longer sampling revealed a decrease in dopamine transients and a time-averaged decrease in the extracellular level . Dopamine transporter inhibition using intravenous GBR 12909 injections increased extracellular dopamine levels changing both frequency and size of dopamine transients in the NAc . To further unmask the mechanics governing extracellular dopamine levels we used intravenous injection of the vesicular monoamine transporter ( Q05940 ) inhibitor , tetrabenazine , to deplete dopamine storage and increase cytoplasmic dopamine in the nerve terminals . 
<mark class="entity" style="background: linear-gradient(90deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB04844
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">MEN</span>
</mark>
 almost abolished phasic dopamine release but increased extracellular dopamine to ∼ 500 nM , presumably by inducing reverse transport by dopamine transporter ( Q01959 ) . Taken together , data presented here show that average extracellular dopamine in the NAc is low ( 20-30 nM ) and largely arises from phasic dopamine transients .</div>

<h2 style="margin: 0">32</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">P51587 interacts with the cytoskeletal linker protein plectin to form a complex controlling centrosome localization . The breast cancer susceptibility gene ( P51587 ) is localized mainly in the nucleus where it plays an important role in DNA damage repair . Some P51587 protein is also present in the centrosome . Here , we demonstrate that P51587 interacts with plectin , a cytoskeletal cross-linker protein , and that this interaction controls the position of the centrosome . Phosphorylation of plectin by cyclin-dependent kinase 1 / cyclin B ( P06493 / CycB ) kinase has been reported to abolish its cross-linking function during mitosis . Here , we induced phosphorylation of plectin in prepared fractions of HeLa cells by adding activated P06493 / CycB kinase . Consequently , there was significant dissociation of the centrosome from the nuclear membrane . Q15149 has six homologous ankyrin-like repeat domains ( termed Q15149 M1 - M6 ) . Using a pull-down assay , we found that Q86UG4 - Q15149 M1 and a Q86UG4 - C-terminal region fusion protein ( which comprised Q15149 M6 , along with an adjacent vimentin site ) interacted with P51587 . Since each Q15149 module exhibits high homology to the others , the possibility of all six domains participating in this interaction was indicated . Moreover , when Q15149 M1 was overexpressed in HeLa cells , it competed with endogenous plectin and inhibited the P51587 - plectin interaction . This inhibitory effect resulted in dissociation of the centrosomes from the nucleus and increased the rate of micronuclei formation which may lead to carcinogenesis . In addition , when either P51587 or plectin was suppressed by the appropriate siRNA , a similar change in centrosomal positioning was observed . We suggest that the P51587 - plectin interaction plays an important role in the regulation of centrosome localization and also that displacement of the centrosome may result in genomic instability and cancer development .</div>

<h2 style="margin: 0">33</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Chenodeoxycholic acid attenuates ovalbumin-induced airway inflammation in murine model of asthma by inhibiting the T ( H ) 2 cytokines . Asthma is a complex highly prevalent airway disease that is a major public health problem for which current treatment options are inadequate . Recently , farnesoid X receptor ( Q96RI1 ) has been shown to exert anti-inflammatory actions in various disease conditions , but there have been no reported investigations of Chenodeoxycholic acid ( 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 ) , a natural Q96RI1 agonist , in allergic airway inflammation . To test the 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 effectiveness in airway inflammation , ovalbumin ( OVA ) - induced acute murine asthma model was established . We found that lung tissue express Q96RI1 and 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 administration reduced the severity of the murine allergic airway disease as assessed by pathological and molecular markers associated with the disease . 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 treatment resulted in fewer infiltrations of cells into the airspace and peribronchial areas , and decreased goblet cell hyperplasia , mucus secretion and serum IgE levels which was increased in mice with OVA-induced allergic asthma . The 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 treatment further blocked the secretion of TH2 cytokines ( P05112 , P05113 and P35225 ) and proinflammatory cytokine P01375 - α indicate that the Q96RI1 and its agonists may have potential for treating allergic asthma .</div>

<h2 style="margin: 0">34</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Farnesoid X receptor activation by chenodeoxycholic acid induces detoxifying enzymes through AMP-activated protein kinase and extracellular signal-regulated kinase 1/2- mediated phosphorylation of CCAAT / enhancer binding protein β . Farnesoid X receptor ( Q96RI1 ) regulates redox homeostasis and elicits a cytoprotective effect . CCAAT / enhancer binding protein-β ( C / EBPβ ) plays a role in regulating the expression of hepatocyte-specific genes and contributes to hepatocyte protection and liver regeneration . In view of the role of Q96RI1 in xenobiotic metabolism and hepatocyte survival , this study investigated the potential of Q96RI1 to activate C / EBPβ for the induction of detoxifying enzymes and the responsible regulatory pathway . Chenodeoxycholic acid ( 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 ) , a major component in bile acids , activates Q96RI1 . In HepG 2 cells , 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 treatment activated C / EBPβ , as shown by increases in its phosphorylation , nuclear accumulation , and expression . 3 - ( 2,6- Dichlorophenyl ) - 4 - ( 3 ' - carboxy - 2 - chlorostilben - 4 - yl - ) oxymethyl - 5 - isopropyl-isoxazole ( GW4064 ) , a synthetic Q96RI1 ligand , had similar effects . In addition , 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 enhanced luciferase gene transcription from the construct containing -1.65- kb P09210 promoter , which contained C / EBP response element ( pGL - 1651 ) . Moreover , 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 treatment activated AMP-activated protein kinase ( AMPK ) , which led to extracellular signal-regulated kinase 1/2 ( P27361 / 2 ) activation , as evidenced by the results of experiments using a dominant-negative mutant of AMPKα and chemical inhibitor . The activation of P27361 / 2 was responsible for the activating phosphorylation of C / EBPβ . Q96RI1 knockdown attenuated the ability of 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 to activate AMPK and P27361 / 2 and phosphorylate C / EBPβ . Consistently , enforced expression of Q96RI1 promoted the phosphorylation of AMPKα , P27361 / 2 , and C / EBPβ , verifying that C / EBPβ phosphorylation elicited by 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 results from the activation of AMPK and P27361 / 2 by Q96RI1 . In mice , 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 treatment activated C / EBPβ with the induction of detoxifying enzymes in the liver . Our results demonstrate that 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 induces antioxidant and xenobiotic-metabolizing enzymes by activating C / EBPβ through AMPK-dependent P27361 / 2 pathway downstream of Q96RI1 .</div>

<h2 style="margin: 0">35</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Activation of farnesoid X receptor attenuates liver injury in systemic lupus erythematosus . To investigate the expression and effect of farnesoid X receptor ( Q96RI1 ) on systemic lupus erythematosus ( SLE ) liver dysfunction and indicate its hepatoprotective role and the immunomodulatory property . mRNA and protein levels of Q96RI1 were determined on the liver specimens of SLE patients with liver injury as well as MRL / lpr rodent models . The Q96RI1 agonist chenodeoxycholic acid ( 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 ) was administrated to MRL / lpr mice and the control BALB / C with concanavalin A ( ConA ) - induced liver injury . Blood samples were taken 0 , 4 , 8 , 12 , 16 , and 24 h after ConA injection for the detection of serum ALT , Q9NRA2 , IFN-γ , P01375 - α , and P05231 . Q96RI1 was down-regulated at both mRNA and protein levels in the liver specimens of SLE patients with liver injury as well as MRL / lpr mice . MRL / lpr was more susceptible to ConA than BALB / C indicated by significantly higher levels of aminotransferase and inflammatory cytokines . Activation of Q96RI1 by 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 significantly reduced aminotransferase and inflammatory cytokines IFN-γ , P01375 - α , and P05231 caused by ConA injection in MRL / lpr mice . Q96RI1 was down-regulated in SLE patients as well as MRL / lpr lupus models with liver dysfunction . Q96RI1 activation ameliorated liver injury and suppressed inflammatory cytokines , thereby showing its protective function in SLE . Our findings raised the promising potential target for the treatment of SLE liver injury .</div>

<h2 style="margin: 0">36</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Preparation of phosphorylated starch by dry-heating in the presence of pyrophosphate and its calcium-phosphate solubilizing ability . Starch was phosphorylated through dry-heating in the presence of pyrophosphate at various conditions , and the characteristics of phosphorylated starch ( PS ) were examined . Starch phosphorylation increases as the pH increases from 3 to 6 , but diminishes at pH 7 . Increased temperatures enhance phosphorylation . Data from ( 31 ) P NMR suggests that starch phosphorylation occurs mainly at the P01024 - OH and P13671 - OH of the glucose residue . The phosphate linkage is mainly due to monostarch monophosphate . Although starch had almost no calcium phosphate-solubilising capacity , this capacity was markedly enhanced by phosphorylation . X-ray diffraction analysis indicates that the crystal structure of hydroxyapatite was not present in the calcium phosphate-PS complex .</div>

<h2 style="margin: 0">37</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Influence of a 3 - day regimen of azithromycin on the disposition kinetics of cyclosporine A in stable renal transplant patients . Some macrolide antibiotics have been shown to produce significant drug-drug interactions through the inhibition of cytochrome P450 ( CYP ) enzymes . In renal transplant patients these interactions pose potentially serious problems for the safe administration of cyclosporine A ( Q13216 ) , a substrate of P08684 . The effects of azithromycin on Q13216 disposition kinetics were evaluated in eight stable renal transplant patients . Patients had been stabilized on individualized doses of Q13216 which remained unchanged throughout the study . 
<mark class="entity" style="background: linear-gradient(90deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB00207
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">MEN</span>
</mark>
 was administered for 3 days . Baseline measurements of Q13216 disposition kinetics were taken prior to azithromycin treatment ( study day 2 ) and after 3 days ( study day 5 ) of azithromycin treatment ( 500mg / day , orally ) . The key parameters of interest were the area under the Q13216 blood concentration versus time curve ( AUC ) measured for 24h after the morning dose of Q13216 on both days 2 and 5 , and the C ( max ) values of Q13216 . The geometric mean ratios ( GMRs ) of those parameters ( day 5 / day 2 ) and their 90 % confidence intervals ( 90 % CI ) were 107 ( 98,116 ) and 119 ( 104,136 ) , respectively . The 7 % increase in exposure level and 19 % increase in peak plasma concentration are not likely to be clinically significant . It is concluded that azithromycin ( 500mg / dayx 3 days ) does not alter the disposition kinetics of Q13216 in a clinically significant way , and that Q13216 dosage adjustments are not warranted in renal transplant patients taking these two drugs together .</div>

<h2 style="margin: 0">38</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Use of RNA interference to elucidate the effect of P04198 on cell cycle in neuroblastoma . BACKGROUND : P04198 amplification marks poor prognosis in neuroblastoma ( NB ) tumors . In evaluating the mechanisms by which retinoic acid ( RA ) or nerve growth factor ( P01138 ) decrease cell number in P04198 amplified NB cells , we have identified a number of proteins whose expression either decreases ( E2F , P06493 , Q00534 , cyclin dependent kinase activity ) or increases ( p27 ) in association with a decrease in P04198 expression . However , it was still unclear which were P04198 dependent effects or not . PROCEDURE : This study aimed to determine which changes in cell cycle gene expression are modulated as a consequence of the decrease in P04198 . We silenced P04198 expression using siRNA targeted to the coding region of P04198 . Then , by using siRNA transient transfections , we analyzed the change of cell cycle related genes and cell cycle in P04198 amplified NB cell lines . RESULTS : We demonstrate that expression of P04198 can be suppressed by almost 60 % in P04198 amplified NB cell using siRNAs targeted to P04198 . Functionally , the decrease in P04198 leads to a decrease in cells in the S-phase of the cell cycle . Decreases in P04198 are associated with decreases in Q01094 - 2 and Q02363 along with increases in p27 protein levels by post-transcriptional modification . Moreover , we find that a decrease in P04198 is accompanied by a decrease in cdk 6 mRNA and protein expression . CONCLUSIONS : These results show that E2F and Q02363 expression is associated with P04198 regulation and that cdk 6 is a possible new transcriptional target of P04198 .</div>

<h2 style="margin: 0">39</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">17 
<mark class="entity" style="background: linear-gradient(90deg, #CC9966, #CC9966); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB00783
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">MENMAX</span>
</mark>

<mark class="entity" style="background: linear-gradient(90deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB00783
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">MEN</span>
</mark>
 - mediated growth inhibition of MDA-MB - 468 cells stably transfected with the estrogen receptor : cell cycle effects . P03372 ( ER ) - negative MDA-MB - 468 human breast cancer cells were stably transfected with wild-type human ER and utilized as a model for investigating estrogen - and aryl hydrocarbon ( Ah ) - responsiveness . Treatment of the stably transfected cells with 10 nM 17 beta-estradiol ( E2 ) resulted in a significant inhibition ( &gt; 60 % ) of cell proliferation and DNA synthesis , which was blocked by 10 ( - 7 ) M ICI 182 780 . Analysis by flow cytometry indicated that treatment with E2 increased the percentage of cells in G0 / P55008 ( from 68.8 to 89.4 ) and decreased cells in S ( from 18.4 to 3.4 ) and G2 / M ( from 12.8 to 7.2 ) phases of the cell cycle . The effects of E2 on the major cyclins , cyclin-dependent kinases and cyclin-dependent kinase inhibitors , retinoblastoma protein ( RB ) , Q01094 , and cyclin-dependent kinase activities were also investigated in the stably transfected MDA-MB - 468 cells . The results demonstrated that the growth inhibitory effects of 10 (-8 ) M E2 in ER stably transfected MDA-MB - 468 cells were associated with modulation of several factors required for cell cycle progression and DNA synthesis , including significant induction of the cyclin-dependent kinase inhibitor p21cip - 1 ( &gt; 4 - fold increase after 12 h ) and decreased Q01094 and P12004 protein levels . These results show that the growth-inhibitory effects of E2 in the stably transfected cells were due to multiple factors which result in growth arrest in G0 / P55008 and inhibition of DNA synthesis .</div>

<h2 style="margin: 0">40</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">The P04626 amplicon in breast cancer : Topoisomerase IIA and beyond . P04626 gene amplification is observed in about 15 % of breast cancers . The subgroup of P04626 - positive breast cancers appears to be heterogeneous and presents complex patterns of gene amplification at the locus on chromosome 17q12 - 21 . The molecular variations within the chromosome 17q amplicon and their clinical implications remain largely unknown . Besides the well-known P11388 gene encoding Topoisomerase IIA , other genes might also be amplified and could play functional roles in breast cancer development and progression . This review will focus on the current knowledge concerning the P04626 amplicon heterogeneity , its clinical and biological impact and the pitfalls associated with the evaluation of gene amplifications at this locus , with particular attention to P11388 and the link between P11388 and anthracycline benefit . In addition it will discuss the clinical and biological implications of the amplification of ten other genes at this locus ( MED 1 , Q14849 , Q14451 , P10827 , P10276 , IGFPB 4 , P32248 , P35900 , P08727 and P01350 ) in breast cancer .</div>

<h2 style="margin: 0">41</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Overexpression of Q14849 in human monocyte / macrophages induces an anti-atherogenic lipid phenotype . Dysregulated macrophage cholesterol homoeostasis lies at the heart of early and developing atheroma , and removal of excess cholesterol from macrophage foam cells , by efficient transport mechanisms , is central to stabilization and regression of atherosclerotic lesions . The present study demonstrates that transient overexpression of Q14849 { START [ P49675 ( steroidogenic acute regulatory protein ) - related lipid transfer ] domain 3 ; also known as Q14849 ( metastatic lymph node 64 ) } , an endosomal cholesterol transporter and member of the ' START ' family of lipid trafficking proteins , induces significant increases in macrophage O95477 ( DB00171 - binding cassette transporter A1 ) mRNA and protein , enhances [ ( 3 ) H ] cholesterol efflux to apo ( apolipoprotein ) AI , and reduces biosynthesis of cholesterol , cholesteryl ester , fatty acids , triacylglycerol and phospholipids from [ ( 14 ) C ] acetate , compared with controls . Notably , overexpression of Q14849 prevents increases in cholesterol esterification in response to acetylated LDL ( low-density lipoprotein ) , blocking cholesteryl ester deposition . Thus enhanced endosomal trafficking via Q14849 induces an anti-atherogenic macrophage lipid phenotype , positing a potentially therapeutic strategy .</div>

<h2 style="margin: 0">42</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">A maternal high-fat diet modulates fetal Q96EB6 histone and protein deacetylase activity in nonhuman primates . In nonhuman primates , we previously demonstrated that a maternal high-fat diet ( MHFD ) induces fetal nonalcoholic fatty liver disease ( NAFLD ) and alters the fetal metabolome . These changes are accompanied by altered acetylation of histone H3 ( H3K14ac ) . However , the mechanism behind this alteration in acetylation remains unknown . As Q96EB6 is both a lysine deacetylase and a crucial sensor of cellular metabolism , we hypothesized that Q96EB6 may be involved in fetal epigenomic alterations . Here we show that in utero exposure to a MHFD , but not maternal obesity per se , increases fetal H3K14ac with concomitant decreased Q96EB6 expression and diminished in vitro protein and histone deacetylase activity . MHFD increased H3K14ac and DBC 1 - Q96EB6 complex formation in fetal livers , both of which were abrogated with diet reversal despite persistent maternal obesity . Moreover , MHFD was associated with altered expression of known downstream effectors deregulated in NAFLD and modulated by Q96EB6 ( e . g . , PPARΑ , P37231 , P36956 , P22680 , P49327 , and O00767 ) . Finally , ex vivo purified Q96EB6 retains deacetylase activity on an H3K14ac peptide substrate with preferential activity toward acetylated histone H3 ; mutagenesis of the catalytic domain of Q96EB6 ( H363Y ) abrogates H3K14ac deacetylation . Our data implicate Q96EB6 as a likely molecular mediator of the fetal epigenome and metabolome under MHFD conditions .</div>

<h2 style="margin: 0">43</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells . The higher frequency of lung adenocarcinoma in women smokers than in men smokers suggests a role for gender-dependent factors in the etiology of lung cancer . We evaluated estrogen receptor ( ER ) alpha and beta expression and activity in human lung adenocarcinoma cell lines and normal lung fibroblasts . Q8N1N2 - length ERalpha and ERbeta proteins were expressed in all cell lines with higher ERbeta than ERalpha . Although estradiol ( E ( 2 ) ) binding was similar , E ( 2 ) stimulated proliferation only in cells from females , and this response was inhibited by anti-estrogens 4 - hydroxytamoxifen ( DB04468 ) and DB00947 . In contrast , E ( 2 ) did not stimulate replication of lung adenocarcinoma cells from males and DB04468 or ICI did not block cell proliferation . Similarly , transcription of an estrogen response element-driven reporter gene was stimulated by E ( 2 ) in lung adenocarcinoma cells from females , but not males . P06401 ( PR ) expression was increased by E ( 2 ) in two out of five adenocarcinoma cell lines from females , but none from males . E ( 2 ) decreased P12830 protein expression in some of the cell lines from females , as it did in MCF - 7 breast cancer cells , but not in the cell lines from males . Thus , ERalpha and ERbeta expression does not correlate with the effect of ER ligands on cellular activities in lung adenocarcinoma cells . On the other hand , coactivator Q15648 expression was higher in lung adenocarcinoma cells from females versus males and higher in adenocarcinoma cells than in normal human bronchial epithelial cells . Q15648 and other ER coregulators may contribute to differences in estrogen responsiveness between lung adenocarcinoma cells in females and males .</div>

<h2 style="margin: 0">44</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">The nuclear hormone receptor farnesoid X receptor ( Q96RI1 ) is activated by androsterone . Farnesoid X receptor ( Q96RI1 ) uses bile acids as endogenous ligands . Here , we demonstrate that androsterone , a metabolic product of testosterone , is also an Q96RI1 ligand . Treatment of castrated male mice with androsterone induced expression of the Q96RI1 target gene small heterodimer partner ( Q15466 ) . In mouse AML - 12 hepatocytes , chenodeoxycholic acid ( 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 ) or androsterone induced Q15466 expression with a similar kinetic pattern . The Q96RI1 antagonist guggulsterone blocked the induction of Q15466 by androsterone in AML - 12 cells . Nuclear magnetic resonance spectroscopy demonstrated the direct binding of androsterone to purified human Q96RI1 ( hFXR ) ligand-binding domain ( LBD ) protein , resulting in the recruitment of steroid receptor coactivator protein - 1 ( Q15788 ) coactivator peptide . In HEK 293 cells , androsterone activated gal 4 - mouse Q96RI1 - LBD and gal 4 - hFXR-LBD fusion proteins , although in contrast to 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 , androsterone activation was significantly greater for the mouse Q96RI1 - LBD than for the hFXR-LBD . Site-directed mutagenesis of the hFXR-LBD defined amino acids Asn 354 and Ser 345 as critical for differential species sensitivity to 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 and androsterone , respectively . Crystal structure studies suggest that the orientation of the steroid nucleus of bile acids within the binding pocket of Q96RI1 is reversed from all other nuclear hormone receptors . In support of this model , we show here that mutations M265I or R331H , residues predicted by crystal structure to interact with the carboxylic acid tail of 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 but not with androsterone , altered 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 activation but had no effect on androsterone activation . Activation of Q96RI1 by androsterone may provide an additional means for physiological or pharmacological modulation of Q96RI1 .</div>

<h2 style="margin: 0">45</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">P48061 and [ N33A ] P48061 in 5637 and HeLa cells : regulating P00533 phosphorylation via calmodulin / calcineurin . In the human neoplastic cell lines 5637 and HeLa , recombinant P48061 elicited , as expected , downstream signals via both G-protein-dependent and β-arrestin-dependent pathways responsible for inducing a rapid and a late wave , respectively , of P27361 / 2 phosphorylation . In contrast , the structural variant [ N33A ] P48061 triggered no β-arrestin-dependent phosphorylation of P27361 / 2 , and signaled via G protein-dependent pathways alone . Both P48061 and [ N33A ] P48061 , however , generated signals that transinhibited P00533 phosphorylation via intracellular pathways . 1 ) Prestimulation of P61073 / P00533 - positive 5637 or HeLa cells with P48061 modified the HB - P01133 - dependent activation of P00533 by delaying the peak phosphorylation of tyrosine 1068 or 1173 . 2 ) Prestimulation with the synthetic variant [ N33A ] P48061 , while preserving P61073 - related chemotaxis and P61073 internalization , abolished P00533 phosphorylation . 3 ) In cells knockdown of β-arrestin 2 , P48061 induced a full inhibition of P00533 like [ N33A ] P48061 in non-silenced cells . 4 ) P00533 phosphorylation was restored as usual by inhibiting PCK , calmodulin or calcineurin , whereas the inhibition of CaMKII had no discernable effect . We conclude that both recombinant P48061 and its structural variant [ N33A ] P48061 may transinhibit P00533 via G-proteins / calmodulin / calcineurin , but [ N33A ] P48061 does not activate β-arrestin-dependent P27361 / 2 phosphorylation and retains a stronger inhibitory effect . Therefore , we demonstrated that P48061 may influence the magnitude and the persistence of signaling downstream of P00533 in turn involved in the proliferative potential of numerous epithelial cancer . In addition , we recognized that [ N33A ] P48061 activates preferentially G-protein-dependent pathways and is an inhibitor of P00533 .</div>

<h2 style="margin: 0">46</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Benzyl isothiocyanate ( BITC ) inhibits migration and invasion of human gastric cancer AGS cells via suppressing P29323 signal pathways . Metastasis suppressors and associated other regulators of cell motility play a critical initial role in tumor invasion and metastases . Benzyl isothiocyanate ( BITC ) is a hydrolysis compound of glucotropaeolin in dietary cruciferous vegetables . BITC has been found to exhibit prevention of cancers in laboratory animals and might also be chemoprotective in humans . Here , the purpose of this study was to investigate the effects of BITC on cell proliferation , migration , invasion and mitogen-activated protein kinase ( MAPK ) pathways of AGS human gastric cancer cells . Wound healing and Boyden chamber ( migration and invasion ) assays demonstrated that BITC exhibited an inhibitory effect on the abilities of migration and invasion in AGS cancer cells . BITC suppressed cell migration and invasion of AGS cells in a dose-dependent manner . Results from Western blotting indicated that BITC exerted an inhibitory effect on the P27361 / 2 , Ras , P62993 , Rho A , P35228 , P35354 for causing the inhibitions of P08253 , - 7 and - 9 then followed by the inhibitions of invasion and migration of AGS cells in vitro . BITC also promoted O14733 , Q99759 , c-jun , P45983 / 2 , P15692 , Sos 1 , phosphoinositide 3 - kinase ( PI3K ) , PKC , nuclear factor-kappaB ( NF-κB ) p65 in AGS cells . Results from real-time polymerized chain reaction ( PCR ) showed that BITC inhibited the gene expressions of P08253 , - 7 - 9 , Q05397 , Q13464 and RhoA after BITC treatment for 24 and 48 hours in AGS cells . Taken together , the finding may provide new mechanisms and functions of BITC , which inhibit migration and invasion of human gastric cancer AGS cells .</div>

<h2 style="margin: 0">47</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus : the influence of acute hyperinsulinemia , very-low calorie diet and Q07869 - α agonist treatment . The aim of our study was to measure serum concentrations of fibroblast growth factor 19 ( O95750 ) in patients with obesity ( OB ) , obesity and type 2 diabetes mellitus ( T2DM ) and healthy subjects ( C ) at baseline and after selected interventions . We measured serum O95750 levels and other biochemical and hormonal parameters in 29 OB and 19 T2DM females and 30 sex - and age-matched control subjects . The interventions were acute hyperinsulinemia during isoglycemic-hyperinsulinemic clamp ( n = 11 for T2DM and 10 for C ) , very-low calorie diet ( VLCD , n = 12 for OB ) and 3 months treatment with Q07869 agonist fenofibrate ( n = 11 for T2DM ) . Baseline serum O95750 levels were significantly lower in OB relative to C group ( 132.1+ / -12.7 vs . 202.2+ / -16.7 pg / ml , p &lt; 0.05 ) , while no significant difference was observed between T2DM and OB or control group . Acute hyperinsulinemia tended to decrease O95750 levels in both healthy and T2DM subjects . Three weeks of VLCD in OB group had no significant effect on O95750 , whereas three months of fenofibrate treatment markedly reduced O95750 levels in T2DM patients ( 194.58+ / -26.2 vs . 107.47+ / -25.0 pg / ml , p &lt; 0.05 ) . We conclude that O95750 levels in our study were at least partially dependent upon nutritional status , but were not related to parameters of glucose metabolism or insulin sensitivity .</div>

<h2 style="margin: 0">48</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">1,25- dihydroxyvitamin D3 and its receptor inhibit the chenodeoxycholic acid-dependent transactivation by farnesoid X receptor . Farnesoid X receptor ( Q96RI1 ) , the receptor for bile acids , including chenodeoxycholic acid ( 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 ) , is a member of the nuclear receptor superfamily , which also includes the receptors for retinoic acid , vitamin D ( D3 ) , thyroid hormone , thiazolidinedione and 22 ( R ) - hydroxycholesterol . Here , we have evaluated the effects of a series of ligands and their receptors on the promoter activity induced by 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 / Q96RI1 . The kidney cell line , CV1 , was cotransfected with Q96RI1 - expression plasmid and the luciferase-based reporter gene that has a thymidine kinase promoter fused to the canonical Q96RI1 - responsive element or the natural promoter for the small heterodimer partner ( Q15466 ) , bile salt export pump ( O95342 ) , and ileum bile acid ( P51161 ) gene . D3 and its receptor ( P11473 ) inhibited the transactivation of all four reporter constructs that are enhanced by 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 / Q96RI1 . The effect of D3 on the expression of the O95342 and Q15466 genes in HepG 2 cells and that of the P51161 gene in Caco - 2 cells were confirmed by reverse transcription ( RT ) - PCR . Deletion analysis of P11473 revealed that its ligand-binding domain ( LBD ) is responsible for the repression and the DNA-binding domain ( DBD ) is dispensable . Specific interaction between Q96RI1 and P11473 was detected with the in vitro pull-down assay using chimeric Q96RI1 or P11473 fused to glutathione-S-transferase .</div>

<h2 style="margin: 0">49</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Farnesoid X receptor responds to bile acids and represses cholesterol 7alpha - hydroxylase gene ( P22680 ) transcription . DB04540 7alpha - hydroxylase gene ( P22680 ) transcription is repressed by bile acids . The goal of this study is to elucidate the mechanism of P22680 transcription by bile acid-activated farnesoid X receptor ( Q96RI1 ) in its native promoter and cellular context and to identify Q96RI1 response elements in the gene . In Chinese hamster ovary cells transfected with retinoid X receptor alpha ( RXRalpha ) / Q96RI1 , only chenodeoxycholic acid ( 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 ) and deoxycholic acid ( DB08809 ) were able to stimulate a heterologous promoter / reporter containing an ecdysone response element . In HepG 2 cells , all bile acids ( 25 microM ) were able to repress P22680 / luciferase reporter activity , and only 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 and DB08809 further repressed reporter activity when cotransfected with RXRalpha / Q96RI1 . The concentration of 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 required to inhibit 50 % of reporter activity ( IC ( 50 ) ) was determined to be approximately 25 microM without Q96RI1 and 10 microM with Q96RI1 . Deletion analysis revealed that the bile acid response element located between nucleotides - 148 and - 128 was the Q96RI1 response element , but RXRalpha / Q96RI1 did not bind to this sequence . These results suggest that bile acid-activated Q96RI1 exerts its inhibitory effect on P22680 transcription by an indirect mechanism , in contrast to the stimulation and binding of Q96RI1 to intestinal bile acid-binding protein gene promoter . Results also reveal that bile acid receptors other than Q96RI1 are present in HepG 2 cells .</div>

<h2 style="margin: 0">50</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">[ Expression and regulation of megalin in gallbladder mucosa associated with cholesterol gallstone disease ] . OBJECTIVE : To explore the relationship between expression and regulation of P98164 in gallbladder mucosa and cholesterol gallstone disease . METHODS : Gallbladder mucosa , gallbladder wall , bile , gallstone were collected from 29 patients with cholesterol gallstone disease ( GS ) and 12 patients with gallstone free ( P52945 ) . Lipids of bile and stone were measured by kits . Expression of P98164 and O60494 was analyzed by Real-time PCR . GBC-SD cell line were treated with T0901317 , 9 - cis retinoic acid , chenodeoxycholic acid ( 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 ) , the agonists of LXR , RXR , Q96RI1 , respectively . Gene expressions were detected . RESULTS : Biliary cholesterol % molar and CSI increased significantly in GS group [ ( 7.98 + / - 0.44 ) mol % vs ( 4.87 + / - 0.39 ) mol % , P &lt; 0.01 ] . P98164 expression in GS group was significantly higher than that in P52945 group ( P &lt; 0.05 ) and cubilin expression was similar between two groups . In vitro experiments showed that 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 markedly increased expression of megalin . CONCLUSION : This study shows that the increased expression P98164 may help to increase cholesterol uptake in gallbladder and play a compensative role in GS . Q96RI1 may participate in the transcription regulating of P98164 .</div>

<h2 style="margin: 0">51</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Farnesoid X receptor protects liver cells from apoptosis induced by serum deprivation in vitro and fasting in vivo . The farnesoid X receptor ( Q96RI1 ) is a key metabolic regulator in the liver by maintaining the homeostasis of liver metabolites . Recent findings suggest that Q96RI1 may have a much broader function in liver physiology and pathology . In the present work , we identify a novel role of Q96RI1 in protecting liver cell from apoptosis induced by nutritional withdrawal including serum deprivation in vitro or starvation in vivo . Two Q96RI1 ligands , chenodeoxycholic acid ( 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 ) and GW4064 , rescued HepG 2 cells from serum deprivation-induced apoptosis in a dose-dependent manner . This effect of Q96RI1 on apoptotic suppression was compromised when Q96RI1 was knocked down by short interfering RNA . Similarly , the effects of both 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 and GW4064 were abolished after inhibition of the MAPK pathway by a specific inhibitor of MAPK kinase 1/2 . Immunoblotting results indicated that Q96RI1 activation by 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 and GW4064 induced P27361 / 2 phosphorylation , which was attenuated by serum deprivation . In vivo , Q96RI1 ( - / - ) mice exhibited an exacerbated liver apoptosis and lower levels of phosphorylated - P27361 / 2 compared to wild-type mice after starvation . In conclusion , our results suggest a novel role of Q96RI1 in modulating liver cell apoptosis .</div>

<h2 style="margin: 0">52</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">NO modulates the molecular basis of rat interscapular brown adipose tissue thermogenesis . Molecular mechanisms underlying interscapular brown adipose tissue ( Q12908 ) thermogenesis were elucidated . Namely , gene and / or protein expression of uncoupling protein 1 ( P25874 ) , peroxisome proliferator-activated receptor gamma ( PPARgamma ) , PPARgamma-coactivator - 1alpha ( P20142 - 1alpha ) , vascular endothelial growth factor ( P15692 ) and proliferating cell nuclear antigen ( P12004 ) - key molecules that regulate thermogenesis-related processes - mitochondriogenesis , angiogenesis and Q12908 hyperplasia , in rats subjected to cold ( 4 + / - 1 degrees C ) for 1 , 3 , 7 , 12 , 21 and 45days were investigated . Particularly , to examine influence of nitric oxide ( NO ) on Q12908 thermogenic-program , cold-exposed animals were treated by l-arginine or N ( omega ) - nitro-l-arginine-methyl ester ( L-NAME ) . Related to control ( 22 + / - 1 degrees C ) , cold induced time-coordinated P25874 , PPARgamma and P20142 - 1alpha transcriptional activation accompanied by P12004 activation and increased P15692 immunolabeling that correlate with endothelial NO synthase ( P29474 ) transcriptional activation suggesting NO involvement in these thermogenic-factors activation . Observed molecular changes were translated into increased mitochondrial-remodeling , angiogenesis , and Q12908 hyperplasia . l - DB00125 augmented and prolonged cold-induced increase of P29474 , inducible NOS and thermogenic-molecules expression , Q12908 nerve supply , vascularity , hyperplasia and mitochondrial-remodeling , while L-NAME had an opposite effects . Results show that NO improves thermogenesis-related mitochondriogenesis , angiogenesis and tissue hyperplasia , positively affecting molecular basis of these processes , suggesting that NO is an essential regulator of Q12908 thermogenic-program operating , at genes , proteins and tissue structure levels .</div>

<h2 style="margin: 0">53</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">O95750 promotes progression of prostate cancer . BACKGROUND : Fibroblast growth factor ( FGF ) signaling pathways have been reported to play important roles in prostate cancer ( PCa ) progression . O95750 is one of a subfamily of FGFs that circulate in serum and act in an endocrine manner . Our objective was to investigate its role in the progression of PCa . METHODS : The effect of O95750 on the proliferation and epithelial-mesenchymal transition of LNCaP and PC3 cells was examined using MTT assay and Western blotting . Serum concentration of O95750 was measured by ELISA in 209 patients with PCa , and the association between clinicopathological features and the presence of O95750 - positive cells in tissues derived from 155 patients who undergone radical prostatectomy was investigated . RESULTS : Under androgen-deprived conditions achieved by incubation in medium with O95750 , the expression of P19022 in LNCaP cells was enhanced , that of P12830 and caspase 3 was suppressed , and the viability of LNCaP and PC3 cells was significantly enhanced . Significantly higher levels of PSA were recorded in the group determined by immunohistochemistry staining to be O95750 - positive ( P = 0.0046 ) . The 5 - year biochemical recurrence-free survival rate after radical prostatectomy was 46.4 % in the O95750 - positive group and 70.0 % in the O95750 - negative group ( P = 0.0027 ) . In multivariate analysis , the presence of O95750 - positive tissues was an independent factor for worse prognosis after radical prostatectomy ( P = 0.0052 ) . Serum O95750 levels in high Gleason grade group were higher than that in low Gleason grade group ( P = 0.0009 ) . CONCLUSIONS : O95750 might be associated with biochemical recurrence after radical prostatectomy by promoting cell proliferation and epithelial-mesenchymal transition of PCa .</div>

<h2 style="margin: 0">54</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">The regulation of sterol metabolism by cell interactions . Total and free cholesterol levels in P13671 glial cells are regulated by a cell interaction-dependent mechanism that operates independently of exogenous cholesterol and serum lipoproteins . This mechanism , which is activated by changes in culture density , coordinately regulates the activities of P04035 and acyl - DB01992 : cholesterol acyltransferase ( ACAT ) . Both enzyme activities are low in sparse density cultures , rise as density increases from sparse to moderate , and decrease with further density increases . When culture density is abruptly elevated , both enzyme activities decay rapidly and with biphasic kinetics . Neither enzyme phosphorylation nor diffusible cytosolic factors appear to be directly involved in density suppression of P04035 . Studies with human fibroblasts that are defective in P01130 function demonstrate that density regulation does not require a functional P01130 . Extracellular matrix and soluble factors have also been ruled out as intercellular mediators . The specific growth rate of P13671 cultures changes with density in the same manner as sterol metabolism . The possibility that growth and sterol metabolism are regulated by a common cell interaction-dependent mechanism is discussed .</div>

<h2 style="margin: 0">55</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Steatohepatitis in laboratory opossums exhibiting a high lipemic response to dietary cholesterol and fat . Plasma VLDL and LDL cholesterol were markedly elevated ( &gt; 40 - fold ) in high-responding opossums , but moderately elevated ( 6 - fold ) in low-responding opossums after they had consumed a high-cholesterol and high-fat diet for 24 wk . In both high - and low-responding opossums , plasma triglycerides were slightly elevated , threefold and twofold , respectively . Dietary challenge also induced fatty livers in high responders , but not in low responders . We studied the lipid composition , histopathological features , and gene expression patterns of the fatty livers . Free cholesterol ( 2 - fold ) , esterified cholesterol ( 11 - fold ) , and triglycerides ( 2 - fold ) were higher in the livers of high responders than those in low responders , whereas free fatty acid levels were similar . The fatty livers of high responders showed extensive lobular disarray by histology . Inflammatory cells and ballooned hepatocytes were also present , as were perisinusoidal fibrosis and ductular proliferation . In contrast , liver histology was normal in low responders . Hepatic gene expression revealed differences associated with the development of steatohepatitis in high responders . The accumulation of hepatic cholesterol was concomitant with upregulation of the P04035 gene and downregulation of the Q02318 , Q9H221 , and P21439 genes . Genes involved in inflammation ( P01375 , P19838 , and P35354 ) and in oxidative stress ( P13498 and P14598 ) were upregulated . Upregulation of the growth factor genes ( PDGF and P01137 ) and collagen genes ( Col 1A1 , Col 3A1 , and Col 4A1 ) was consistent with fibrosis . Some of the histological characteristics of the fatty livers of high-responding opossums imitate those in the livers of humans with nonalcoholic steatohepatitis .</div>

<h2 style="margin: 0">56</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">The farnesoid X receptor induces very low density lipoprotein receptor gene expression . The farnesoid X receptor ( Q96RI1 ) is a nuclear receptor activated by bile acids ( BAs ) . In response to ligand-binding , Q96RI1 regulates many genes involved in BA , lipid , and lipoprotein metabolism . To identify new Q96RI1 target genes , microarray technology was used to profile total RNA extracted from HepG 2 cells treated with the natural Q96RI1 agonist chenodeoxycholic acid ( 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 ) . Interestingly , a significant increase of transcript level of the very low density lipoprotein receptor ( P98155 ) was observed . Our data , resulting from selective Q96RI1 activation , Q96RI1 RNA silencing and Q96RI1 - deficient mice , clearly demonstrate that BAs up-regulate P98155 transcript levels via a Q96RI1 - dependent mechanism in vitro in human and in vivo in mouse liver cells .</div>

<h2 style="margin: 0">57</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Histone acetyltransferase-dependent chromatin remodeling and the vascular clock . Rhythmic gene expression is central to the circadian control of physiology in mammals . Transcriptional activation of Per and Cry genes by heterodimeric bHLH - DB00233 proteins is a key event in the feedback loop that drives rhythmicity ; however , the mechanism is not clearly understood . Here we show the transcriptional coactivators and histone acetyltransferases , p300 / CBP , Q92831 , and Q9Y6Q9 associate with the bHLH - DB00233 proteins , O15516 and Q99743 , to regulate positively clock gene expression . Furthermore , Cry 2 mediated repression of Q99743 : O00327 is overcome by overexpression of p300 in transactivation assays . Accordingly , p300 exhibits a circadian time-dependent association with Q99743 in the vasculature , which precedes peak expression of target genes . In addition , a rhythm in core histone H3 acetylation on the mPer 1 promoter in vivo correlates with the cyclical expression of their mRNAs . Temporal coactivator recruitment and O60235 - dependent chromatin remodeling on the promoter of clock controlled genes in the vasculature permits the mammalian clock to orchestrate circadian gene expression .</div>

<h2 style="margin: 0">58</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Synthesis , biological activity and HPLC validation of 1,2 , 3,4- tetrahydroacridine derivatives as acetylcholinesterase inhibitors . The synthesis and biochemical evaluation of new hybrids of tacrine ( 
<mark class="entity" style="background: linear-gradient(90deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB00382
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">MEN</span>
</mark>
 ) and 4 - fluorobenzoic acid ( 4 - FBA ) possessing activity towards acetylcholinesterase ( P22303 ) and butyrylcholinesterase ( BuChE ) inhibition are presented . The compounds of interest were obtained from the reaction of activated 4 - FBA and diamino derivatives of 1,2 , 3,4- tetrahydroacridine . The compounds P13671 - 2KW / HCl , P13671 - 4KW / HCl and P13671 - 3KW / HCl have four-fold higher antiacetylcholinesterase activity than 
<mark class="entity" style="background: linear-gradient(90deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB00382
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">MEN</span>
</mark>
 . All of the acquired compounds present higher selectivity towards P22303 than 
<mark class="entity" style="background: linear-gradient(90deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB00382
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">MEN</span>
</mark>
 and lower selectivity towards BuChE . In addition , a rapid , selective and stability-indicating HPLC method was developed and validated for the determination of P13671 - 2KW / HCl , P13671 - 3KW / HCl and P13671 - 4KW / HCl . 
<mark class="entity" style="background: linear-gradient(90deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB00382
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">MEN</span>
</mark>
 and 4 - FBA were found to be the main impurities . Chromatographic separation was achieved isocratically on a Waters Symmetry C18 150 × 3.9 mm , 4 μm column with a mobile phase of acetonitrile / buffer ( 17 mM sodium dodecyl sulphate and 8.3 mM sodium dihydrogen phosphate , 50:50 v / v ) ( overall pH 4 ) . A 1.5 ml / min flow rate and a 247 nm wavelength were chosen for this method . P13671 - 2KW / HCl , P13671 - 3KW / HCl and P13671 - 4KW / HCl were subjected to acidic and basic hydrolysis , chemical oxidation , thermal exposition at 60 ° C and intense UV light . The limits of detection ( LOD ) and quantification ( LOQ ) were less than 2 μg / ml and 6 μg / ml for P13671 - 2KW / HCl , P13671 - 3KW / HCl and P13671 - 4KW / HCl , 0.04 μg / ml and 0.12 μg / ml for 
<mark class="entity" style="background: linear-gradient(90deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB00382
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">MEN</span>
</mark>
 , 0.42 μg / ml and 1.41 μg / ml for 4 - FBA , respectively .</div>

<h2 style="margin: 0">59</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Modeling of Q14654 and inhibition mechanism of the natural ligand , ellagic acid , using molecular docking . Diabetes mellitus is a disorder in which blood sugar ( glucose ) levels are abnormally high because the body does not produce enough insulin to meet its needs . Post-prandial hyperglycemia ( PPHG ) is an independent risk factor for the development of macro vascular complications . It is now recognized that normalizing post-prandial blood glucose is more difficult than normalizing fasting glucose . DB01345 channels are the most widely distributed type of ion channel and are found in virtually all living organisms . The function of KATP channels is best understood in pancreatic beta cells , the membrane potential of which is responsive to external glucose concentration . Beta cells show a remarkably complex electrical bursting behavior in response to an increase in glucose level . DB00731 and 
<mark class="entity" style="background: linear-gradient(90deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB00222
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">MEN</span>
</mark>
 are a class of insulin secretagog agents that lowers blood glucose levels by stimulating insulin secretion from the pancreas . These compounds interact with the DB00171 - sensitive potassium ( K + DB00171 ) channel in pancreatic beta cells . However , the side effects of these drugs overpass their uses , and the need to identify compounds with less adverse effects is exigent . In our research study , we used the natural compound ellagic acid , which is an already proven anti-carcinogen , anti-mutagen , and anticancer initiator , for its anti-diabetic activity in comparison to the two commercial drugs ( DB00731 and 
<mark class="entity" style="background: linear-gradient(90deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB00222
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">MEN</span>
</mark>
 ) . The drugs and the compounds were docked to the DB00171 - dependent potassium channel and their energy value showed that the compound had higher binding value than the commercial drugs . Then an ADME / Tox analysis for the compound was carried out which showed that ellagic can be a possible lead molecule .</div>

<h2 style="margin: 0">60</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo . Expression of the chemokine receptor P61073 allows breast cancer cells to migrate towards specific metastatic target sites which constitutively express P48061 . In this study , we determined whether this interaction could be disrupted using short-chain length heparin oligosaccharides . Radioligand competition binding assays were performed using a range of heparin oligosaccharides to compete with polymeric heparin or heparan sulphate binding to I ( 125 ) P48061 . DB01109 dodecasaccharides were found to be the minimal chain length required to efficiently bind P48061 ( 71 % inhibition ; P &lt; 0.001 ) . These oligosaccharides also significantly inhibited P48061 - induced migration of P61073 - expressing LMD MDA-MB 231 breast cancer cells . In addition , heparin dodecasaccharides were found to have less anticoagulant activity than either a smaller quantity of polymeric heparin or a similar amount of the low molecular weight heparin pharmaceutical product , 
<mark class="entity" style="background: linear-gradient(90deg, #CC9966, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06822
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">MEN</span>
</mark>
 . When given subcutaneously in a SCID mouse model of human breast cancer , heparin dodecasaccharides had no effect on the number of lung metastases , but did however inhibit ( P &lt; 0.05 ) tumour growth ( lesion area ) compared to control groups . In contrast , polymeric heparin significantly inhibited both the number ( P &lt; 0.001 ) and area of metastases , suggesting a differing mechanism for the action of polymeric and heparin-derived oligosaccharides in the inhibition of tumour growth and metastases .</div>

<h2 style="margin: 0">61</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">P12004 D1b represses breast cancer cell growth by antagonizing the action of cyclin D1a on estrogen receptor alpha-mediated transcription . Alternate splicing of the cyclin D1 gene gives rise to transcripts a and b which encode two protein isoforms cyclin D1a and cyclin D1b . P12004 D1a can substitute for estrogen to activate estrogen receptor alpha - ( ERalpha ) mediated transcription and can induce the proliferation of estrogen responsive tissues . However , little is known about the biological role of cyclin D1b in transcriptional regulation . In this study , we determined that cyclin D1b is incapable of inducing ERalpha-mediated transcription because it fails to recruit steroid receptor coactivator - 1 ( Q15788 ) to ERalpha . Moreover , cyclin D1b antagonizes cyclin D1a - induced ERalpha-mediated transcription by competing with cyclin D1a for ERalpha binding . Cell proliferation assay showed that cyclin D1b repressed the ERalpha-positive breast cancer T47D cell growth . Our findings suggest that the cyclin D1b represses breast cancer cell growth by antagonizing the action of cyclin D1a on ERalpha-mediated transcription .</div>

<h2 style="margin: 0">62</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Pathways targeted by antidiabetes drugs are enriched for multiple genes associated with type 2 diabetes risk . Genome-wide association studies ( GWAS ) have uncovered &gt; 65 common variants associated with type 2 diabetes ( T2D ) ; however , their relevance for drug development is not yet clear . Of note , the first two T2D - associated loci ( P37231 and Q14654 / Q09428 ) encode known targets of antidiabetes medications . We therefore tested whether other genes / pathways targeted by antidiabetes drugs are associated with T2D . We compiled a list of 102 genes in pathways targeted by marketed antidiabetic medications and applied Gene Set Enrichment Analysis ( MAGENTA [ Meta-Analysis Gene-set Enrichment of variaNT Associations ] ) to this gene set , using available GWAS meta-analyses for T2D and seven quantitative glycemic traits . We detected a strong enrichment of drug target genes associated with T2D ( P = 2 × 10 ( - 5 ) ; 14 potential new associations ) , primarily driven by insulin and thiazolidinedione ( TZD ) targets , which was replicated in an independent meta-analysis ( Metabochip ) . The glycemic traits yielded no enrichment . The T2D enrichment signal was largely due to multiple genes of modest effects ( P = 4 × 10 ( - 4 ) , after removing known loci ) , highlighting new associations for follow-up ( P33121 , P19838 , P11168 , incretin targets ) . Furthermore , we found that TZD targets were enriched for LDL cholesterol associations , illustrating the utility of this approach in identifying potential side effects . These results highlight the potential biomedical relevance of genes revealed by GWAS and may provide new avenues for tailored therapy and T2D treatment design .</div>

<h2 style="margin: 0">63</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Farnesoid X receptor agonist for the treatment of liver and metabolic disorders : focus on 6 - ethyl - 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 . 6 - ethyl-chedeoxycholic acid ( 6E - 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 ) is a farnesoid X receptor ( Q96RI1 ) ligand endowed with agonistic activity under development for treatment of cholestatic liver diseases including primary biliary cirrhosis ( P10515 ) and liver-related metabolic disorders including non-alcoholic fatty liver disease ( NAFLD ) and non-alcoholic steatohepatitis ( NASH ) . Q96RI1 is a bile sensor that acts in coordination with other nuclear receptors to regulate essential steps of bile acid uptake , metabolism and excretion . 6E - 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 has been investigated in preclinical models of cholestasis , liver fibrosis and diet-induced atherosclerosis . In a phase II clinical trial in patients with P10515 , 6E - 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 met the primary endpoint of a reduction in alkaline phosphatase levels but safety data indicated that the drug exacerbated pruritus , one of the main symptoms of P10515 , suggesting that 6E - 
<mark class="entity" style="background: linear-gradient(90deg, #003300, #ffffff); padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DB06777
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem">SUB</span>
</mark>
 or Q96RI1 are mediators of pruritus in humans . Treatment of patients with diabetes and liver steatosis resulted in amelioration of insulin sensitivity despite a reduction a slight reduction in HDL and increased levels of LDL were observed . These side effects on bile acids and lipid metabolism were all predicted by pre-clinical studies , suggesting that potent Q96RI1 ligands hold promise but potential side effects might limit their development .</div>

</figure>
</body>
</html>

